[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 296
1. Chen JS, Hsieh PS, Chiang JM, Yeh CY, Tsai WS, Tang R, Changchien CR, Wu RC: Clinical outcome of signet ring cell carcinoma and mucinous adenocarcinoma of the colon. Chang Gung Med J; 2010 Jan-Feb;33(1):51-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome of signet ring cell carcinoma and mucinous adenocarcinoma of the colon.
  • BACKGROUND: The purpose of this study was to evaluate the clinicopathologic features and prognosis of signet ring cell carcinoma (SCC) and non-SCC mucinous adenocarcinoma (MC) and to compare them with those of nonmucinous adenocarcinoma (NMC) of the colon.
  • The rate of spread of tumors in TNM stage IV via hematogenous routes (liver, lung, bone, and brain) was significantly lower in SCC patients (5/28, 17.9%) than in MC (40/104, 38.5%) and in NMC patients (417/694, 60.1%).
  • The role of resection for late stage SCC should be carefully evaluated.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Signet Ring Cell / pathology. Colonic Neoplasms / pathology

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20184795.001).
  • [ISSN] 2309-835X
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


2. Kanzaki H, Hirasaki S, Suzuki S, Matsubara M, Fujita K, Koide N: Early stage of colonic adenocarcinoma associated with traditional serrated adenoma. Intern Med; 2007;46(23):1911-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early stage of colonic adenocarcinoma associated with traditional serrated adenoma.
  • We describe a 68-year-old woman diagnosed as having a colonic adenocarcinoma associated with traditional serrated adenoma (SA) with submucosal invasion of the sigmoid colon.
  • Colonoscopy revealed a 0-IIa+IIc colon cancer with a SA component, about 12 mm in diameter, in the sigmoid colon.
  • She underwent laparoscopy-assisted resection of the sigmoid colon.
  • In the resected specimen, colon cancer with mucin pools was adjacent to the SA.
  • Cases of colonic adenocarcinoma associated with traditional SA with submucosal invasion are relatively rare.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Sigmoid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18057763.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Kim KY, Kee MK, Chong SA, Nam MJ: Galanin is up-regulated in colon adenocarcinoma. Cancer Epidemiol Biomarkers Prev; 2007 Nov;16(11):2373-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Galanin is up-regulated in colon adenocarcinoma.
  • The early diagnosis of colorectal cancer and the early detection of recurrence are central to effective treatment, as prognosis is directly related to the stage of the disease.
  • When colorectal cancer is diagnosed at an early, localized stage, 5-year survival is 90%.
  • We have implemented an approach based on the analysis of microarray data for the identification of tumor proteins that may have utility as biomarkers in colon cancer.
  • Expression analysis of microarray data obtained from a variety of 290 tumors and normal tissues revealed that galanin was maximally expressed in colon cancer.
  • These findings were corroborated by real-time quantitative PCR, in which the colon cancer cell lines LOVO, HCT15, SW480, and SW620 cell showed significantly higher levels of galanin expression than did noncolon cancer cell lines.
  • To evaluate galanin as a potential biomarker of colon cancer, a preliminary "training" set of serum from 40 healthy donors and 55 colon cancer patients was analyzed by ELISA.
  • The data pattern was confirmed by an independent set of 90 masked serum samples: 24 from healthy donors and 66 from colon cancer patients.
  • The galanin expression level was significantly increased with tumor size and tumor stage.
  • These findings justify a prospective assessment of serum galanin protein as a screening tool for colon cancer.
  • [MeSH-major] Adenocarcinoma / blood. Biomarkers, Tumor / blood. Colonic Neoplasms / blood. Galanin / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18006926.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 88813-36-9 / Galanin
  •  go-up   go-down


Advertisement
4. Puppa G, Maisonneuve P, Sonzogni A, Masullo M, Chiappa A, Valerio M, Zampino MG, Franceschetti I, Capelli P, Chilosi M, Menestrina F, Viale G, Pelosi G: Independent prognostic value of fascin immunoreactivity in stage III-IV colonic adenocarcinoma. Br J Cancer; 2007 Apr 10;96(7):1118-26
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Independent prognostic value of fascin immunoreactivity in stage III-IV colonic adenocarcinoma.
  • In this study, we investigated the expression of fascin in 228 advanced colonic adenocarcinoma patients with a long follow-up.
  • Fascin correlated significantly with sex, tumour grade and stage, mucinous differentiation, number of metastatic lymph nodes, extranodal tumour extension, and the occurrence of distant metastases.
  • [MeSH-major] Adenocarcinoma / metabolism. Carrier Proteins / metabolism. Colonic Neoplasms / metabolism. Microfilament Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1993 Feb 15;71(4):1368-83 [8435813.001]
  • [Cites] J Cutan Pathol. 2002 Aug;29(7):430-8 [12139639.001]
  • [Cites] Am J Pathol. 1996 Feb;148(2):593-600 [8579121.001]
  • [Cites] In Vivo. 1996 Mar-Apr;10(2):153-60 [8744794.001]
  • [Cites] J Cell Biol. 1996 Sep;134(5):1271-81 [8794867.001]
  • [Cites] Hum Pathol. 1996 Nov;27(11):1124-34 [8912819.001]
  • [Cites] Dis Colon Rectum. 1997 Jan;40(1):15-24 [9102255.001]
  • [Cites] Mol Biol Cell. 1997 Nov;8(11):2345-63 [9362073.001]
  • [Cites] Mol Biol Cell. 1998 May;9(5):993-1006 [9571235.001]
  • [Cites] J Cell Biol. 1998 Oct 5;143(1):121-33 [9763425.001]
  • [Cites] J Biol Chem. 1999 Feb 26;274(9):5443-53 [10026156.001]
  • [Cites] CA Cancer J Clin. 2004 Nov-Dec;54(6):295-308 [15537574.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):416-21; discussion 421 [12368669.001]
  • [Cites] Am J Pathol. 2003 Jan;162(1):69-80 [12507891.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):241-50 [12525515.001]
  • [Cites] Br J Cancer. 2003 Feb 24;88(4):537-47 [12592367.001]
  • [Cites] Eur J Cancer. 2003 Apr;39(6):718-27 [12651195.001]
  • [Cites] Lung Cancer. 2003 Nov;42(2):203-13 [14568688.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1572-82 [15117979.001]
  • [Cites] Histopathology. 1986 May;10(5):437-59 [3721406.001]
  • [Cites] J Cell Biol. 1986 Aug;103(2):631-40 [3525578.001]
  • [Cites] Cell Struct Funct. 1988 Oct;13(5):373-85 [3224379.001]
  • [Cites] Oncology. 2004;67(3-4):262-70 [15557788.001]
  • [Cites] Surg Oncol. 2004 Aug-Nov;13(2-3):93-101 [15572091.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):186-92 [15671545.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2597-605 [15814639.001]
  • [Cites] Int J Biochem Cell Biol. 2005 Sep;37(9):1787-804 [16002322.001]
  • [Cites] Hum Pathol. 2005 Jul;36(7):741-6 [16084942.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Nov 11;337(1):355-62 [16185662.001]
  • [Cites] Semin Oncol. 2005 Dec;32(6 Suppl 8):11-4 [16360006.001]
  • [Cites] Clin Colorectal Cancer. 2006 May;6(1):38-45 [16796790.001]
  • [Cites] Eur J Cardiothorac Surg. 2006 Sep;30(3):538-42 [16870459.001]
  • [Cites] J Clin Pathol. 2006 Sep;59(9):958-64 [16524962.001]
  • [Cites] BMC Cancer. 2006;6:241 [17029629.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1362-6 [14571738.001]
  • [Cites] J Histochem Cytochem. 2000 Feb;48(2):163-6 [10639482.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1739-57 [10738234.001]
  • [Cites] Br J Cancer. 2000 Oct;83(7):870-3 [10970687.001]
  • [Cites] Clin Exp Metastasis. 2000;18(1):83-8 [11206843.001]
  • [Cites] J Cell Biol. 2001 Mar 19;152(6):1169-82 [11257118.001]
  • [Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2754-9 [11753948.001]
  • [Cites] Bioessays. 2002 Apr;24(4):350-61 [11948621.001]
  • [Cites] Am J Clin Pathol. 2002 Jul;118(1):52-9 [12109856.001]
  • [Cites] DNA Cell Biol. 1994 Aug;13(8):821-7 [8068206.001]
  • (PMID = 17375048.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Microfilament Proteins; 146808-54-0 / fascin
  • [Other-IDs] NLM/ PMC2360113
  •  go-up   go-down


5. Wang W, Li YF, Sun XW, Chen G, Zhan YQ, Huang CY, Wan DS, Pan ZZ, Zhou ZW: Correlation analysis between loss of heterozygosity at chromosome 18q and prognosis in the stage-II colon cancer patients. Chin J Cancer; 2010 Aug;29(8):761-7
Genetic Alliance. consumer health - Chromosome 18q-.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation analysis between loss of heterozygosity at chromosome 18q and prognosis in the stage-II colon cancer patients.
  • In this study we detected the frequency of loss of heterozygosity (LOH) at chromosome 18q and investigated the relationship between LOH and clinicopathologic features and its prognostic value for patients with stage II colon cancer.
  • METHODS: A total of 106 samples of tumor tissues and corresponding normal mucosa from patients with sporadic stage-II colon cancer were included in this study.
  • Multivariate analysis for association between LOH and prognosis in colon cancer patients was performed with Cox proportional hazards regression model.
  • LOH was more frequent on the left-side, poorly-differentiated adenocarcinoma, and nonmucinous colon cancers.
  • The occurrence of 18q-LOH is an independent poor prognostic factor for the patients with stage-II colon cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosomes, Human, Pair 18 / genetics. Colonic Neoplasms / genetics. Loss of Heterozygosity
  • [MeSH-minor] Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Papillary / genetics. Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Papillary / surgery. Adult. Age Factors. Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Grading. Neoplasm Staging. Proportional Hazards Models. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20663324.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


6. Sträter J, Herter I, Merkel G, Hinz U, Weitz J, Möller P: Expression and prognostic significance of APAF-1, caspase-8 and caspase-9 in stage II/III colon carcinoma: caspase-8 and caspase-9 is associated with poor prognosis. Int J Cancer; 2010 Aug 15;127(4):873-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and prognostic significance of APAF-1, caspase-8 and caspase-9 in stage II/III colon carcinoma: caspase-8 and caspase-9 is associated with poor prognosis.
  • To study their prognostic influence in colon carcinoma, expression of APAF-1, caspase-8 and caspase-9 was determined by immunohistochemistry in normal colon mucosa (n = 8) and R0-resected stage II/III colon carcinomas (n >or= 124) using a semiquantitative score.
  • In normal colon, APAF-1 and caspase-8 are most strongly expressed in the luminal surface epithelium, whereas caspase-9 is expressed all along the crypt axis.
  • In colon carcinomas, there is considerable variability in the expression of these proapoptotic factors, although complete loss of caspase-8 and caspase-9 is rare.
  • The influence of caspase-8 expression was mainly seen in patients with stage III colon carcinoma (p = 0.011), whereas the prognostic influence of caspase-9 expression was significant in stage II cases (p = 0.037) and just failed to be significant in stage III tumors (p = 0.0581).
  • Our data suggest that, in colon carcinomas, expression of caspase-8 and caspase-9 is significantly associated with poor survival.
  • Caspase-9 may be an independent prognosticator in colon carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma, Mucinous / metabolism. Apoptotic Protease-Activating Factor 1 / metabolism. Biomarkers, Tumor / metabolism. Caspase 8 / metabolism. Caspase 9 / metabolism. Colonic Neoplasms / metabolism
  • [MeSH-minor] Aged. Colon / metabolism. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20013803.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / APAF1 protein, human; 0 / Apoptotic Protease-Activating Factor 1; 0 / Biomarkers, Tumor; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspase 9
  •  go-up   go-down


7. Ohsawa T, Ishida H, Kumamoto K, Nakada H, Yokoyama M, Okada N, Ishibashi K, Haga N: Resection of stage 0/I colon cancer via a circumferential periumbilical skin incision: relevance to single-incision laparoscopic surgery. Tech Coloproctol; 2010 Dec;14(4):311-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resection of stage 0/I colon cancer via a circumferential periumbilical skin incision: relevance to single-incision laparoscopic surgery.
  • BACKGROUND: We have been performing curative resection of colon cancer via a minilaparotomy without utilizing any laparoscopic instruments as an alternative to laparoscopic-assisted approach.
  • Based on our experiences and improved surgical techniques, we have devised a new method for performing resection of stage 0/I colon cancer via a circumferential periumbilical skin incision that is associated with better cosmesis than standard minilaparotomy.
  • METHODS: The short- and long-term results of curative colectomy via a circumferential periumbilical skin incision without utilizing any laparoscopic instruments performed in selected patients with stage 0/I colon cancer between October 2003 and July 2004 were analyzed.
  • Pathological stage according the TNM classification was stage 0 in 4 patients and stage I in 6 patients.
  • CONCLUSION: Curative colectomy via a circumferential periumbilical skin incision seems oncologically safe, yields satisfactory cosmetic results, and may provide an alternative to single-incision laparoscopic surgery in selected patients with colon cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Colectomy / methods. Colonic Neoplasms / surgery. Laparotomy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20730550.001).
  • [ISSN] 1128-045X
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


8. Law CC, Fu YT, Chau KK, Choy TS, So PF, Wong KH: Toxicity profile and efficacy of oral capecitabine as adjuvant chemotherapy for Chinese patients with Stage III colon cancer. Dis Colon Rectum; 2007 Dec;50(12):2180-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxicity profile and efficacy of oral capecitabine as adjuvant chemotherapy for Chinese patients with Stage III colon cancer.
  • PURPOSE: The Xeloda in Adjuvant Cancer Therapy trial, conducted in a white population of patients, established capecitabine (Xeloda) as adjuvant chemotherapy for Stage III colon cancer.
  • Given the ethnical difference in toxicity of adjuvant chemotherapy in colon cancer, this study was designed to evaluate the safety and efficacy of adjuvant capecitabine in Chinese patients with colon cancer.
  • METHODS: Chinese patients with curatively resected Stage III colon adenocarcinoma, who received adjuvant capecitabine, were entered into a prospective database.
  • CONCLUSIONS: A different toxicity profile of adjuvant capecitabine was noted in this study on Chinese patients with colon cancer compared with that reported in the Xeloda in Adjuvant Cancer Therapy trial, whereas the efficacy outcomes were comparable.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / adverse effects. Colonic Neoplasms / drug therapy. Deoxycytidine / analogs & derivatives. Fluorouracil / analogs & derivatives

  • Genetic Alliance. consumer health - Oral cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17963003.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Prodrugs; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Read TE, Fleshman JW, Caushaj PF: Sentinel lymph node mapping for adenocarcinoma of the colon does not improve staging accuracy. Dis Colon Rectum; 2005 Jan;48(1):80-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel lymph node mapping for adenocarcinoma of the colon does not improve staging accuracy.
  • PURPOSE: This study was designed to: determine the efficacy of sentinel lymph node mapping in patients with intraperitoneal colon cancer; and create an algorithm to predict potential survival benefit by using best-case estimates in favor of sentinel node mapping and lymph node ultraprocessing techniques.
  • METHODS: Forty-one patients with intraperitoneal colon cancer undergoing colectomy with curative intent were studied prospectively.
  • After mobilization of the colon and mesentery, 1 to 2 ml of isosulfan blue dye was injected subserosally around the tumor.
  • Stage of disease in the remaining 38 patients was: I, n = 10 (26 percent); II, n = 15 (39 percent); III, n = 11 (29 percent); IV, n = 2 (5 percent).
  • To create a survival benefit algorithm, we assumed the following: combined fraction of Stage I and II disease (0.5); fraction understaged by bivalving and hematoxylin and eosin staining that would have occult positive nodes by more sophisticated analysis (0.15); fraction of occult positive nodes detected by sentinel node mapping (0.9); and survival benefit from chemotherapy (0.33).
  • CONCLUSIONS: Sentinel node mapping with isosulfan blue dye and routine processing of retrieved nodes does not improve staging accuracy in patients with intraperitoneal colon cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Algorithms. Colonic Neoplasms / pathology. Neoplasm Staging / methods. Sentinel Lymph Node Biopsy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15690662.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Quah HM, Chou JF, Gonen M, Shia J, Schrag D, Landmann RG, Guillem JG, Paty PB, Temple LK, Wong WD, Weiser MR: Identification of patients with high-risk stage II colon cancer for adjuvant therapy. Dis Colon Rectum; 2008 May;51(5):503-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of patients with high-risk stage II colon cancer for adjuvant therapy.
  • PURPOSE: Adjuvant therapy for Stage II colon cancer remains controversial but may be considered for patients with high-risk features.
  • The purpose of this study was to assess the prognostic significance of commonly reported clinicopathologic features of Stage II colon cancer to identify high-risk patients.
  • METHODS: We analyzed a prospectively maintained database of patients with colon cancer who underwent surgical treatment from 1990 to 2001 at a single specialty center.
  • We identified 448 patients with Stage II colon cancer who had been treated by curative resection alone, without postoperative chemotherapy.
  • Univariate and multivariate analyses identified three independent features that significantly affected disease-specific survival: tumor Stage T4 (hazard ratio (HR), 2.7; 95 percent confidence interval (CI), 1.1-6.2; P = 0.02), preoperative carcinoembryonic antigen > 5 ng/ml (HR, 2.1; 95 percent CI, 1.1-4.1; P = 0.02), and presence of lymphovascular or perineural invasion (HR, 2.1; 95 percent CI, 1-4.4; P = 0.04).
  • CONCLUSIONS: Patients with Stage II colon cancer generally have an excellent prognosis.
  • Use of commonly reported clinicopathologic features accurately stratifies Stage II colon cancer by disease-specific survival.
  • [MeSH-major] Adenocarcinoma / surgery. Colonic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18322753.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Tracy RA, Chuang ST, Kim J, Coppola D: Correlation of expression of pro-apoptotic proteins bax and bak with lymph node metastasis in colonic adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15042

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of expression of pro-apoptotic proteins bax and bak with lymph node metastasis in colonic adenocarcinoma.
  • : e15042 Background: Colon cancer has been associated with disturbances in the regulation of apoptosis.
  • Here we investigate how these two pro-apoptotic markers correlate with lymph node (LN) metastasis in colonic adenocarcinoma (CA).
  • The findings suggest a role for these markers in predicting stage and patient survival in colonic adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964458.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Lenehan PF, Fry DW, Heyman ER, Eliason JF, Worzel WP: Generation and validation of a primary-tumor-derived four-gene prognostic signature for recurrence (R) of stages I/II colorectal cancer (CRC) following potentially curative resection. J Clin Oncol; 2009 May 20;27(15_suppl):4035

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Archival formalin-fixed paraffin-embedded (FFPE) primary adenocarcinoma tissues obtained at initial resection with curative intent were retrieved for 145 stage I/II (pT1-4 pN0 M0) CRC pts from multiple international sites; none had neoadjuvant or adjuvant therapy.
  • RR by stage (I/II) = 7.00/7.28 and tumor site (colon/rectum) = 8.75/4.50.
  • CONCLUSIONS: A GP derived 4-gene prognostic test using FFPE tumor tissue can differentiate early stage CRC pts at high versus low risk for R within 3y better than current NCCN Guidelines.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961545.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Perazzo F, Denninghoff V, Pasccon G, Pallotta MG, Tatangelo M, Cuartero V, Kirchuck R, Chacón M, Gennari L, Vera K, Avagnina A: Preliminary report of the mutation status of KRAS and BRAF-V600E in an Argentinean population of primary colorectal tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e22183

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary tumor site was 21.9% (32) right colon, 5.5% (8) transverse colon, 45.2% (66) left colon and 27.4%(40) rectal cancer.
  • Adenocarcinoma was the unique histotype and mucinous differentiation was observed in 14.7% (21).
  • The Pathological Stage at diagnosis was Stage I 3.42% (5), II 24% (35), III 33.6% (49) and IV 39% (57).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963599.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Overman MJ, Hu C, Wolff RA, Chang GJ: Impact of lymph node evaluation on survival for small bowel adenocaricnoma: Analysis of the Surveillance, Epidemiology and End Results (SEER) database. J Clin Oncol; 2009 May 20;27(15_suppl):4596

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 4596 Background: Small bowel adenocarcinoma is a rare malignancy and is often associated with poor outcome.
  • METHODS: Patients aged 18-90 with adenocarcinoma of the small intestine diagnosed between 1988 and 2005 were identified from SEER data (ver. 2008).
  • Cox proportional hazards regression analyses were performed after adjusting for age, sex, race, T stage, grade, and primary site.
  • Stage I-II cases were categorized by total LN examined (1-8, 9-12, and >12).
  • Stage III cases were evaluated using cut-point analysis to determine the number of positive LN that predicted outcomes.
  • Survival among stage I/II patients (n=1,216) was dependent upon the total number of LN assessed.
  • 5-year DSS for stage II patients was 66%, 82% (HR 0.52 95% CI .33-.84), and 88% (HR 0.38, 95% CI .23-.61) for 1-8, 9-12, >12 LN, respectively.
  • The optimal cutpoint of positive LN for stage III disease (n=775) was <3 compard to ≥3 with 5 year DSS of 58% vs. 37% (HR 1.49, 95% CI 1.15-1.92, P=0.002), respectively.
  • Among stage III patients, the LNR was even more predictive of survival than stratification by the number of positive lymph nodes as demonstrated by an improved chi-square statistic for the multivariate model (78.8 vs 63.1, P=0.0005).
  • CONCLUSIONS: As noted in colon cancer, the total number of LN assessed has considerable influence upon survival in stage I, II and III small bowel adenocarcinoma.
  • Stratifying stage III small bowel adenocarcinoma into those with <3 and ≥3 positive lymph nodes significantly improves prognostication for these patients and future staging systems should incorporate the number of positive nodes into nodal staging.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963112.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Bayraktar UD, Bayraktar S, Herna S, Ku N, Jones C, Merchan J, Sands LR, Marchetti F, Montero A, Rocha-Lima CM: Does delay of adjuvant chemotherapy affect the clinical outcome in patients with colon cancer? J Clin Oncol; 2009 May 20;27(15_suppl):4046

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does delay of adjuvant chemotherapy affect the clinical outcome in patients with colon cancer?
  • : 4046 Background: Adjuvant chemotherapy (AC) in patients with stage III colon adenocarcinoma prevents recurrences and improves survival.
  • We hypothesized that AC commenced within 60 days of resection would increase survival in patients with stage II and III colon cancer.
  • METHODS: Patients with newly diagnosed stage II or III colon adenocarcinoma who received fluoropyrimidine based AC in two centers (a private cancer center and a large community hospital) between 2000 and 2007 were included into analysis.
  • 116 patients (61%) were female and 35 patients (18%) had stage II disease.
  • The only difference between the two groups was the higher N stage in group 1.
  • The treating hospital and the N stage were found to be the factors affecting the OS in univariate analysis.
  • CONCLUSIONS: Delay of AC more than 60 days after resection is associated with inferior survival in stage II/III colon cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961564.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Kim J, Chae Y, Sohn S, Kang B, Lee S, Lim K, Choi G, Baek J: -93G&gt;A polymorphism of hMLH1 associated with prognosis for patients with colorectal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4039

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Three hundred and ninety- seven consecutive patients with curatively resected colorectal adenocarcinoma were enrolled in the present study.
  • RESULTS: The median age of the patients was 63 years (range, 21-85), and 218 (54.9%) patients had colon cancer and 179 (45.1%) patients rectal cancer.
  • Pathologic stages after surgery were as follows: stage 0/I (n=86, 21.7%), stage II (n=146, 36.8%), stage III (n=145, 36.5%), and stage IV (n=20, 5.0%).
  • Multivariate survival analysis including stage, differentiation, age, and CEA level showed that the survival for the patients with the -93AA genotype of hMLH1 was worse than for the patients with the combined -93GG and GA genotype (overall survival: hazard ratio [HR]=2.953, 95% Confidential Interval [CI], 1.273-6.850, P=0.012; disease-free survival: HR=2.299, 95% CI, 1.417-3.730, P=0.001), whereas the other polymorphisms were not associated with survival.
  • Accordingly, in addition to the pathologic stage, the analysis of -93G>A polymorphism of hMLH1 can help identify patient subgroups at high risk of a poor disease outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961540.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Szajda SD, Snarska J, Jankowska A, Roszkowska-Jakimiec W, Puchalski Z, Zwierz K: Cathepsin D and carcino-embryonic antigen in serum, urine and tissues of colon adenocarcinoma patients. Hepatogastroenterology; 2008 Mar-Apr;55(82-83):388-93

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cathepsin D and carcino-embryonic antigen in serum, urine and tissues of colon adenocarcinoma patients.
  • However such a marker, distinctive for this particular carcinoma and allowing its detection at a sufficiently early stage of development has not yet been found.
  • CEA undergoes expression in all kinds of adenocarcinoma and is found both intercellularly and extracellularly.
  • The objective of this study has been to evaluate CD activity in the blood serum, urine and tumor tissues as well as in the colon biopsies which were not changed macroscopically and CEA concentration in the serum of colon adenocarcinoma, considering the extent of spread of cancer (TNM), the grade of the differentiation of cancer cell (G) as well as the tumor size.
  • The possibility of application of CD along with CEA as markers of colon adenocarcinoma has also been examined.
  • METHODOLOGY: The examination included the serum and urine of 21 patients as well as 12 tissues biopsies with histopathologically confirmed colon adenocarcinoma.
  • The reference group for the blood and urine comprised of 17 healthy controls, and for the colon adenocarcinoma tissues- samples collected from 14 people from the sites most distant from the resected tumor on the boundaries which were free of cancer cells.
  • RESULTS: CD activity was increased in the blood serum (p < 0.0001) and tissues (p = 0.022) of colon adenocarcinoma patients in comparison to the reference group.
  • CD specific activity has tendency to increase in colon adenocarcinoma tissues (p = 0.441) as compared to the reference group.
  • By examining data in regard to TNM clinical-histopathological classification, G and the tumor size, it could be concluded that CD activity in serum and urine in colon adenocarcinoma patients depends on progress of cancer in which CD activity increases with TNM.
  • A statistically significant increase in CEA concentration was found in the serum of colon adenocarcinoma patients, which was almost threefold higher than the in reference group.
  • CONCLUSIONS: The results of this study suggest that examination of CD activity and CEA concentration in serum, as well as CD activity in the urine, might be used in oncological diagnostics of colon adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / chemistry. Adenocarcinoma / metabolism. Carcinoembryonic Antigen / analysis. Cathepsin D / analysis. Colonic Neoplasms / chemistry. Colonic Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18613372.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; EC 3.4.23.5 / Cathepsin D
  •  go-up   go-down


18. Castiglione F, Taddei A, Buccoliero AM, Garbini F, Gheri CF, Freschi G, Bechi P, Rossi Degl'Innocenti D, Taddei GL: TNM staging and T-cell receptor gamma expression in colon adenocarcinoma. Correlation with disease progression? Tumori; 2008 May-Jun;94(3):384-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TNM staging and T-cell receptor gamma expression in colon adenocarcinoma. Correlation with disease progression?
  • Several studies showed the gamma-delta T-cell receptor repertoire of intestinal adenocarcinoma.
  • METHODS: A total of 58 patients with colon adenocarcinoma was included in the analysis.
  • We used the TNM staging system to grade colon cancer.
  • CONCLUSIONS: The results showed statistical significance between the presence of T-cell receptor gamma and N1/N2 stage lymph nodes (P = 0.001).
  • [MeSH-major] Adenocarcinoma / immunology. Adenocarcinoma / pathology. Biomarkers, Tumor / analysis. Colonic Neoplasms / immunology. Colonic Neoplasms / pathology. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Receptors, Antigen, T-Cell, gamma-delta / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705407.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Antigen, T-Cell, gamma-delta
  •  go-up   go-down


19. Tsiambas E, Rigopoulos DN, Kravvaritis C, Lazaris AC, Kavantzas N, Niotis A, Niotis TH, Tsounis D, Karameris A, Patsouris E: Chromogenic in situ hybridization analysis of EGFR gene copies in colon adenocarcinoma based on intra-operative imprints and tissue microarrays. J Gastrointestin Liver Dis; 2009 Sep;18(3):293-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromogenic in situ hybridization analysis of EGFR gene copies in colon adenocarcinoma based on intra-operative imprints and tissue microarrays.
  • BACKGROUND: Although Epidermal Growth Factor Receptor (EGFR) over expression is a frequent event in colon adenocarcinoma (CA), identification of EGFR gene deregulation mechanisms--combined to k-ras mutations--remains the basic criterion for rational application of anti-EGFR targeted therapeutic strategies.
  • Significant association was established by correlating stage to chromosome 7 (p=0.024).
  • Furthermore, chromosome 7 aneuploidy is associated with a more advanced stage in CA.
  • [MeSH-major] Adenocarcinoma / genetics. Colonic Neoplasms / genetics. Gene Dosage. Genes, erbB-1. In Situ Hybridization / methods. Tissue Array Analysis / methods

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19795022.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Romania
  •  go-up   go-down


20. Korsgaard M, Pedersen L, Sørensen HT, Laurberg S: Delay of treatment is associated with advanced stage of rectal cancer but not of colon cancer. Cancer Detect Prev; 2006;30(4):341-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delay of treatment is associated with advanced stage of rectal cancer but not of colon cancer.
  • BACKGROUND: Dukes' stage is the most important predictor of prognosis of colorectal cancer, but the association between delay of treatment (DT) and Dukes' stage is still controversial.
  • DT was determined through questionnaire-interviews, and Dukes' stage was obtained from medical records and pathological forms.
  • Dukes' stage was classified into two groups: non-advanced (Dukes' stage A or B) and advanced (Dukes' stage C or D) cancer.
  • Using relative risk (RR) the association between DT and stage was estimated, with short delay as the reference group.
  • RESULTS: The RR of advanced cancer was 1.0 (95% confidence intervals (CI): 0.8-1.3) for colon cancer patients with an intermediate DT, and 1.1 (95% CI: 0.9-1.4) for patients with a long DT.
  • CONCLUSION: DT was strongly associated with advanced stage of rectal cancer, but not of colon cancer.
  • [MeSH-minor] Adenocarcinoma / classification. Adenocarcinoma / etiology. Adenocarcinoma / therapy. Adult. Aged. Aged, 80 and over. Female. Humans. Interviews as Topic. Male. Middle Aged. Neoplasm Staging. Practice Patterns, Physicians'. Prospective Studies. Risk Factors. Surveys and Questionnaires. Time Factors

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16965875.001).
  • [ISSN] 0361-090X
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


21. Yamamoto S, Yoshimura K, Konishi F, Watanabe M: Phase II trial to evaluate laparoscopic surgery for Stage 0/I rectal carcinoma. Jpn J Clin Oncol; 2008 Jul;38(7):497-500
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial to evaluate laparoscopic surgery for Stage 0/I rectal carcinoma.
  • Recently reported randomized controlled trials demonstrated that laparoscopic surgery (LS) was comparable or superior to open surgery with regard to the long-term outcome for colon and rectosigmoidal carcinoma; however, controversy persists with regard to the appropriateness of LS for patients with rectal carcinoma.
  • To examine the technical and oncological feasibility of LS for rectal carcinoma, a phase II trial was started in patients with a preoperative diagnosis of Stage 0/I rectal carcinoma, under the direction of the Japan Society of Laparoscopic Colorectal Surgery.
  • The primary end-point in the first stage is the anastomotic leakage rate by double-stapling technique and that in the second stage is overall survival.
  • [MeSH-major] Adenocarcinoma / surgery. Laparoscopy. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18586667.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


22. Safaee A, Moghimi-Dehkordi B, Fatemi SR, Ghiasi S, Nemati-Malek F, Zali MR: Characteristics of colorectal mucinous adenocarcinoma in Iran. Asian Pac J Cancer Prev; 2010;11(5):1373-5
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of colorectal mucinous adenocarcinoma in Iran.
  • AIMS AND BACKGROUND: Mucinous adenocarcinoma (MA) colorectal cancer accounts for 10 to 15% of colorectal carcinoma.
  • It is generally thought that patients with MA present at a more advanced stage of disease and have a poorer prognosis than those with other types of carcinoma.
  • Patients evaluated on the basis of sex, age, location of tumor, stage, differentiation of tumor and family history of cancer.
  • Most tumors were presented in right colon.
  • 54.3% of MA patients had advanced stage lesions.
  • Survival of the patients was related to disease stage (P = 0.023).
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Colorectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21198295.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


23. Maggard MA, Yermilov I, Tomlinson JS, Ko CY: Are 12 nodes needed to accurately stage T1 and T2 colon cancers? Dig Dis Sci; 2009 Mar;54(3):640-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are 12 nodes needed to accurately stage T1 and T2 colon cancers?
  • Evaluation of 12 lymph nodes has been mandated to prevent colon cancer understaging.
  • Given that the probability of node metastases is largely associated with T-stage, are <12 nodes substandard for T1 and T2 lesions?
  • In SEER, 61,237 patients undergoing colon cancer resection were identified.
  • For each T-stage, 5-year survival rates were compared for node-negative cancers by using stepwise node cut-point comparisons (4 nodes, <4, etc.).
  • In conclusion, the number of nodes to stage T1 and T2 lesions may be <12.
  • [MeSH-major] Adenocarcinoma / pathology. Colon / pathology. Colonic Neoplasms / pathology. Lymphatic Metastasis / diagnosis. Neoplasm Staging / standards

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dig Dis Sci. 2009 Apr;54(4):914-5; author reply 916 [19003528.001]
  • (PMID = 18612817.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Barrier A, Roser F, Boëlle PY, Franc B, Tse C, Brault D, Lacaine F, Houry S, Callard P, Penna C, Debuire B, Flahault A, Dudoit S, Lemoine A: Prognosis of stage II colon cancer by non-neoplastic mucosa gene expression profiling. Oncogene; 2007 Apr 19;26(18):2642-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of stage II colon cancer by non-neoplastic mucosa gene expression profiling.
  • We have assessed the possibility to build a prognosis predictor (PP), based on non-neoplastic mucosa microarray gene expression measures, for stage II colon cancer patients.
  • In conclusion, our study suggests that one can build an accurate PP for stage II colon cancer patients, based on non-neoplastic mucosa microarray gene expression measures.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Cluster Analysis. Female. Humans. Liver Neoplasms / secondary. Male. Middle Aged. Mucous Membrane / metabolism. Mucous Membrane / pathology. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17043639.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


25. Rigopoulos DN, Tsiambas E, Lazaris AC, Kavantzas N, Papazachariou I, Kravvaritis C, Tsounis D, Koliopoulou A, Athanasiou AE, Karameris A, Manaios L, Sergentanis TN, Patsouris E: Deregulation of EGFR/VEGF/HIF-1a signaling pathway in colon adenocarcinoma based on tissue microarrays analysis. J BUON; 2010 Jan-Mar;15(1):107-15
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deregulation of EGFR/VEGF/HIF-1a signaling pathway in colon adenocarcinoma based on tissue microarrays analysis.
  • PURPOSE: Overexpression of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) in colon adenocarcinoma (CA) is a frequent event, whereas specific deregulation mechanisms in the corresponding signaling pathways remain under investigation.
  • Significant associations raised correlating stage to chromosome 7 (p=0.024), HIF 1a expression to tumor anatomical location (p=0.019) and also VEGF to HIF 1a expression (p=0.001), whereas EGFR expression was not associated to EGFR gene copies.
  • [MeSH-major] Adenocarcinoma / chemistry. Colonic Neoplasms / chemistry. Hypoxia-Inducible Factor 1, alpha Subunit / analysis. Receptor, Epidermal Growth Factor / analysis. Signal Transduction. Tissue Array Analysis. Vascular Endothelial Growth Factor A / analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20414936.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


26. Georgescu SO, Neacşu CN, Vintilă D, Popa P, Forţu L, Nistor A, Ferariu D, Târcoveanu E: [Long-term results after surgery for colorectal adenocarcinoma, stage I-III. Problems of prognosis]. Rev Med Chir Soc Med Nat Iasi; 2007 Oct-Dec;111(4):932-9
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term results after surgery for colorectal adenocarcinoma, stage I-III. Problems of prognosis].
  • [Transliterated title] Rezultate la distanţă după tratamentul chirurgical al adenocarcinomului colo-rectal stadiile I-III. Probleme de prognostic.
  • STUDY DESIGN: Prospective study on 142 consecutively cases with stage I to III colorectal adenocarcinomas (TNM AJCC/UICC) in which patients underwent potentially curative surgery in one single public health service (1st Surgical Clinic Iaşi, Romania) between 2004 and 2005.
  • The surgical procedures performed were the following: right colectomy (n = 54; 30%); transverse colectomy (n = 2; 1.4%); left colectomy (n = 19; 13.4%); segmental colon resection with anastomosis (n = 5 ; 3.5%); Hartmann procedure (n = 18; 12.7%); anterior rectal resection (n = 11; 7.7%) and abdominoperineal resection (n = 33; 23.2%).
  • RESULTS: The factors with a significant negative influence in overall survival and 42-months survival rates were: the age over 70 years, the emergency surgery related to cancer's complications, the advanced AJCC/ UICC stage, vascular invasion, perineural invasion, the recurrence of disease, the moderate and lower differentiated adenocarcinoma and incomplete or not performed chemotherapy.
  • CONCLUSION: Even with a radical surgical approach the advanced stage of colorectal adenocarcinoma has a low prognostic, but some other factors have also a high significance in postoperative outcome.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Colectomy / methods. Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18389783.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


27. Blum C, Graham A, Yousefzadeh M, Shrout J, Benjamin K, Krishna M, Hoda R, Hoda R, Cole DJ, Garrett-Mayer E, Reed C, Wallace M, Mitas M: The expression ratio of Map7/B2M is prognostic for survival in patients with stage II colon cancer. Int J Oncol; 2008 Sep;33(3):579-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression ratio of Map7/B2M is prognostic for survival in patients with stage II colon cancer.
  • The tumor samples were extracted from formalin-fixed paraffin-embedded primary tissues derived from patients with Stage II CRC who developed disease recurrence within two years (n=10), or were disease-free for at least 4 years (n=12).
  • This suggests that the expression ratio of Map7/B2M may serve as a valuable prognostic marker in patients with Stage II colon cancer, and potentially guide therapeutic decision making.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 2000 Jun 1;14(11):1332-42 [10837026.001]
  • [Cites] Int J Colorectal Dis. 2007 Aug;22(8):887-95 [17235506.001]
  • [Cites] CA Cancer J Clin. 1999 Jul-Aug;49(4):202-19 [11198882.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):419-29 [11159180.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):416-21; discussion 421 [12368669.001]
  • [Cites] Gynecol Oncol. 2004 Feb;92(2):719-25 [14766275.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1564-71 [15051756.001]
  • [Cites] Cancer Cell. 2004 Jun;5(6):607-16 [15193263.001]
  • [Cites] J Immunol. 1989 Jan 1;142(1):352-8 [2462591.001]
  • [Cites] J Exp Med. 1989 Jan 1;169(1):309-14 [2642530.001]
  • [Cites] N Engl J Med. 1990 Feb 8;322(6):352-8 [2300087.001]
  • [Cites] JAMA. 1990 Sep 19;264(11):1444-50 [2202842.001]
  • [Cites] Cancer Res. 1992 Mar 1;52(5):1201-4 [1737380.001]
  • [Cites] J Cell Biol. 1995 Nov;131(4):1015-24 [7490279.001]
  • [Cites] Tumori. 1997 Jan-Feb;83(1 Suppl):S39-41 [9154066.001]
  • [Cites] Inflamm Bowel Dis. 1998 Aug;4(3):196-202 [9741021.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2817-26 [15591335.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3526-35 [15908663.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2080-7 [16609019.001]
  • [Cites] Clin Cancer Res. 2007 May 15;13(10):2849-54 [17504982.001]
  • [Cites] CA Cancer J Clin. 2007 May-Jun;57(3):168-85 [17507442.001]
  • [Cites] Biotechniques. 2000 Sep;29(3):548-50, 552-4, 556 passim [10997270.001]
  • (PMID = 18695889.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K23 CA093419; United States / NCI NIH HHS / CA / R21 CA097875; United States / NCI NIH HHS / CA / R33 CA097875; United States / NCI NIH HHS / CA / CA097875
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Microtubule-Associated Proteins; 0 / beta 2-Microglobulin
  • [Other-IDs] NLM/ NIHMS388523; NLM/ PMC3399116
  •  go-up   go-down


28. Chin CC, Wang JY, Changchien CR, Huang WS, Tang R: Carcinoma obstruction of the proximal colon cancer and long-term prognosis--obstruction is a predictor of worse outcome in TNM stage II tumor. Int J Colorectal Dis; 2010 Jul;25(7):817-22
MedlinePlus Health Information. consumer health - Intestinal Obstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma obstruction of the proximal colon cancer and long-term prognosis--obstruction is a predictor of worse outcome in TNM stage II tumor.
  • PURPOSE: Colon obstruction is suggested to be a predictor of poor outcome in colon cancer.
  • However, the effect of obstruction on outcome in patients with different tumor-nodes-metastases (TNM) stage cancer has not been fully addressed.
  • The aim of this study is to determine whether colon obstruction predicts surgical and long-term oncologic outcomes in patients with proximal colon cancer.
  • METHODS: A total of 1,492 consecutive patients underwent open resection of primary adenocarcinoma of right colon in a single institution between January 1995 and December 2005.
  • Univariate and multivariate analyses were performed to identify colon obstruction and other predictors of surgical and oncologic outcomes.
  • RESULTS: Among 1,492 patients, 306 (20.5%) patients presented with colon obstruction.
  • Obstruction predicted a worse long-term disease-free survival (DFS) among patients with stage II-III disease (log-rank test, p = 0.0003).
  • The data were stratified by TNM stage.
  • Obstruction predicted a worse DFS among patients with TNM stage II cancer (598 patients; log-rank test, p = 0.001; Cox regression, p = 0.012), but it was not a predictor in TNM stage III cancer patients (424 patients; p = 0.116; p = 0.108).
  • CONCLUSIONS: Colon obstruction was an independent predictor of long-term outcome only in TNM stage II but not in stage III proximal colon cancer.
  • Patients with TNM stage II obstructive colon cancer could be included in future trials of adjuvant therapies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20135321.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


29. Morris M, Platell C, Fritschi L, Iacopetta B: Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients. Br J Cancer; 2007 Mar 12;96(5):701-7
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients.
  • Two recent North American studies have shown that completion of 5-fluorouracil (5FU)-based adjuvant chemotherapy is a major prognostic factor for the survival of elderly stage III colon cancer patients.
  • The study cohort comprised 851 stage III colon cancer patients treated by surgery alone and 461 who initiated the Mayo chemotherapy regime.
  • The current and previous studies demonstrate the importance of completing adjuvant 5-FU-based chemotherapy for colon cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Colonic Neoplasms / drug therapy. Colonic Neoplasms / mortality

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 Sep 1;20(17):3605-16 [12202661.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1491-8 [11896096.001]
  • [Cites] J Clin Oncol. 2002 Oct 1;20(19):3992-8 [12351596.001]
  • [Cites] Br J Cancer. 2003 May 19;88(10):1510-5 [12771914.001]
  • [Cites] Br J Cancer. 2003 Jun 16;88(12):1859-65 [12799627.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2896-903 [12885807.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2898-903 [12912934.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3729-36 [14551292.001]
  • [Cites] Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5860-5 [14676107.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2343-51 [15175436.001]
  • [Cites] Oncology (Williston Park). 2004 May;18(6):751-5; discussion 755-8 [15214594.001]
  • [Cites] Eur J Cancer. 2004 Oct;40(15):2230-6 [15454247.001]
  • [Cites] J Clin Oncol. 1988 Oct;6(10):1653-64 [3049954.001]
  • [Cites] N Engl J Med. 1990 Feb 8;322(6):352-8 [2300087.001]
  • [Cites] JAMA. 1990 Sep 19;264(11):1444-50 [2202842.001]
  • [Cites] J Clin Oncol. 1992 Jul;10(7):1171-5 [1607921.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1879-87 [8410113.001]
  • [Cites] J Clin Oncol. 1994 Jun;12(6):1291-5 [8201391.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):246-50 [8996149.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3537-41 [9817272.001]
  • [Cites] Eur J Cancer. 1998 Nov;34(12):1871-5 [10023308.001]
  • [Cites] Cancer. 2005 Mar 15;103(6):1165-71 [15693031.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1819-25 [15774775.001]
  • [Cites] N Engl J Med. 2005 Jun 30;352(26):2696-704 [15987918.001]
  • [Cites] N Engl J Med. 2005 Jun 30;352(26):2746-8 [15987925.001]
  • [Cites] JAMA. 2005 Dec 7;294(21):2703-11 [16333005.001]
  • [Cites] Dig Surg. 2005;22(6):401-14 [16479107.001]
  • [Cites] J Natl Cancer Inst. 2006 May 3;98(9):610-9 [16670386.001]
  • [Cites] J Clin Oncol. 2006 May 20;24(15):2368-75 [16618946.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):102-9 [17194911.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2412-8 [10561304.001]
  • [Cites] Br J Cancer. 2001 Mar 2;84(5):600-3 [11237378.001]
  • [Cites] Ann Intern Med. 2002 Mar 5;136(5):349-57 [11874307.001]
  • [Cites] J Clin Oncol. 2002 Sep 1;20(17):3617-27 [12202662.001]
  • (PMID = 17299387.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2360063
  •  go-up   go-down


30. Mori T, Hirota T, Ohashi Y, Kodaira S, Prospective Trial of Adjuvant Chemotherapy for Colon Cancer Study Group (PAC): Significance of histologic type of primary lesion and metastatic lymph nodes as a prognostic factor in stage III colon cancer. Dis Colon Rectum; 2006 Jul;49(7):982-92
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of histologic type of primary lesion and metastatic lymph nodes as a prognostic factor in stage III colon cancer.
  • PURPOSE: This study was designed to investigate whether the histologic types of the primary lesion and of metastatic lymph nodes in Stage III colon cancer are useful as prognostic factors.
  • METHODS: Stage III colon cancer patients were enrolled and were divided into two groups: Group W, in which the histologic type of both primary tumors and metastatic lymph nodes was well-differentiated adenocarcinoma; and Group U, in which the primary tumors and the metastatic lymph nodes were of any type other than well-differentiated.
  • CONCLUSIONS: In Stage III colon cancer, the prognosis of cases whose primary lesion and lymph node tissues are both well differentiated is extremely good.
  • [MeSH-major] Adenocarcinoma / pathology. Colonic Neoplasms / pathology

  • Genetic Alliance. consumer health - Metastatic cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16625329.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alkylating Agents; 0 / Antimetabolites, Antineoplastic; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


31. Song W, He YL, Cai SR, Zhang CH, Chen CQ, Peng JJ, Zhan WH: [Clinical features of colorectal mucinous adenocarcinoma]. Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Sep;12(5):487-90
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features of colorectal mucinous adenocarcinoma].
  • OBJECTIVE: To investigate the clinicopathological characteristics and prognosis of colorectal mucinous adenocarcinoma (MAC) and non-mucinous adenocarcinoma (NMAC).
  • METHODS: Clinical data of 2089 cases with colorectal cancer from 1994 to 2007 in our hospital, including 169 patients diagnosed as mucinous adenocarcinoma were analyzed retrospectively.
  • The rates of tumor location in colon (97 cases,57.4% vs 814 cases, 44.3%, in MAC and NMAC) were significantly different (P<0.01).
  • The rate of radical resection (86.4% vs 91.5%), hepatic metastasis (5.3% vs 8.5%) and local recurrence had no significant difference between patients with mucinous and non-mucinous adenocarcinoma (P>0.05).
  • In comparison to NMAC patients, MAC patients were worse in long-term overall survival, the survival of receiving radical resection and of TNM stage (II+III) group (P<0.01).
  • Survivals were not significantly different in TNM stage I and IV groups between mucinous and non-mucinous adenocarcinoma (P>0.05).
  • CONCLUSIONS: Colorectal mucinous adenocarcinoma patients have worse outcome in comparison to non-mucinous adenocarcinoma patients.
  • Mucinous adenocarcinoma may have special biological behavior, which is an independent prognostic factor for patients with colorectal cancer.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Colorectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19742341.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


32. Paduch R, Kandefer-Szerszeń M, Szuster-Ciesielska A, Plewka K: Transforming growth factor-beta1 modulates metalloproteinase-2 and -9, nitric oxide, RhoA and alpha-smooth muscle actin expression in colon adenocarcinoma cells. Cell Biol Int; 2010 Feb;34(2):213-23
Hazardous Substances Data Bank. NITRIC OXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transforming growth factor-beta1 modulates metalloproteinase-2 and -9, nitric oxide, RhoA and alpha-smooth muscle actin expression in colon adenocarcinoma cells.
  • Colon carcinoma invasiveness is a process involving cell-cell and cell-matrix alterations, local proteolysis of the ECM (extracellular matrix) or changes in cytokine and growth factor levels.
  • In order to evaluate the role of TGF-beta1 (transforming growth factor-beta1) and small G protein RhoA in tumour progression, the influence of TGF-beta1 treatment or RhoA-associated kinase inhibitor on the production of NO (nitric oxide) and MMP-2 and MMP-9 (metalloproteinases-2 and -9) was analysed in three human colon adenocarcinoma cell lines (HT29, LS180, SW948) representing different stages of tumour development.
  • All the tested cell lines produced low amounts of MMP-2 and MMP-9. rhTGF-beta1 and the synthetic Rho kinase inhibitor (Y-27632) decreased MMP-2 secretion by colon cancer cells, especially in the most advanced stage of colon cancer. rhTGF-beta1 decreased NO secretion by cells, while Y-27632 had no effect on it.
  • Immunoblotting with anti-RhoA antibodies followed by densitometry revealed that RhoA levels were slightly increased after incubation of colon carcinoma cells (SW948) with rhTGF-beta1. rhTGF-beta1 induced alpha-smooth muscle actin (alpha-SMA) expression, especially in high Duke's grade of colon cancer, while Y-27632 blocked it.
  • Summing up, in colon carcinoma cells, TGF-beta1 and RhoA protein may regulate tumour invasiveness measured as MMP, NO and alpha-SMA expression or assayed using motility data and may be a good target for cancer therapy.
  • [MeSH-major] Adenocarcinoma / metabolism. Colonic Neoplasms / metabolism. Transforming Growth Factor beta1 / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19947919.001).
  • [ISSN] 1095-8355
  • [Journal-full-title] Cell biology international
  • [ISO-abbreviation] Cell Biol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Actins; 0 / Amides; 0 / Pyridines; 0 / Recombinant Proteins; 0 / Transforming Growth Factor beta1; 138381-45-0 / Y 27632; 31C4KY9ESH / Nitric Oxide; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.6.5.2 / rhoA GTP-Binding Protein
  •  go-up   go-down


33. Wang MS, Pan Y, Liu N, Guo C, Hong L, Fan D: Overexpression of DARPP-32 in colorectal adenocarcinoma. Int J Clin Pract; 2005 Jan;59(1):58-61
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of DARPP-32 in colorectal adenocarcinoma.
  • Our aim is to investigate the expression of DARPP-32 protein in colorectal adenocarcinoma.
  • The expression of DARPP-32 in colorectal adenocarcinoma tissues 33/42, 78.57% was higher than that in normal colon epithelial tissues (31/60, 51.67%, p <0.05).
  • There was no significant relationship between the expression of DARPP-32 and the differentiation, metastasis and Dukes' stage of colorectal adenocarcinoma (p >0.05).
  • Both DARPP-32 and its truncated isoform t-DARPP were overexpressed in colorectal adenocarcinoma (t=2.306, p=0.028), while t-DARPP was more frequently detected.
  • [MeSH-major] Adenocarcinoma / metabolism. Colorectal Neoplasms / metabolism. Nerve Tissue Proteins / metabolism. Phosphoproteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15707466.001).
  • [ISSN] 1368-5031
  • [Journal-full-title] International journal of clinical practice
  • [ISO-abbreviation] Int. J. Clin. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dopamine and cAMP-Regulated Phosphoprotein 32; 0 / Nerve Tissue Proteins; 0 / Phosphoproteins
  •  go-up   go-down


34. Chin CC, Wang JY, Yeh CY, Kuo YH, Huang WS, Yeh CH: Metastatic lymph node ratio is a more precise predictor of prognosis than number of lymph node metastases in stage III colon cancer. Int J Colorectal Dis; 2009 Nov;24(11):1297-302
Genetic Alliance. consumer health - Metastatic cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic lymph node ratio is a more precise predictor of prognosis than number of lymph node metastases in stage III colon cancer.
  • OBJECTIVE: The objective of this study is to assess the value of metastatic lymph node ratio (LNR) in predicting disease-free survival (DFS) in patients with stage III adenocarcinoma of the colon.
  • MATERIALS AND METHODS: From 1995 to 2003 inclusively, a total of 624 patients featuring stage III adenocarcinoma of the colon underwent curative resection.
  • In T3/4LNR1 patients (n = 411), there was no difference in survival between those with N1 stage and those with N2 stage.
  • Cox proportional hazards regression analysis revealed that N stage (number of positive lymph nodes) was not a significant factor when LNR was taken into consideration.
  • CONCLUSIONS: LNR is a more precise predictor of 5-year DFS than number of positive lymph nodes (N stage) in patients with stage III colon cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19479270.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


35. Kammula US, Kuntz EJ, Francone TD, Zeng Z, Shia J, Landmann RG, Paty PB, Weiser MR: Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett; 2007 Apr 18;248(2):219-28
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome.
  • Unlike some solid tumors, current evidence indicates that c-Met activation in colon cancer is unrelated to gene mutation, is ligand dependent, and occurs via a paracrine fashion.
  • METHODS: Primary tumor c-Met and HGF mRNA expression was analyzed in 60 colon adenocarcinomas.
  • CONCLUSION: Evaluation of the c-Met receptor in context of ligand, HGF, allows identification of a metastatic phenotype that correlates with advanced stage and poor survival. c-Met and HGF co-expression in the tumor microenvironment could be useful in the molecular staging of colon cancer and viable therapeutic targets.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / analysis. Colonic Neoplasms / pathology. Hepatocyte Growth Factor / biosynthesis. Proto-Oncogene Proteins c-met / biosynthesis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16945480.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 67256-21-7 / Hepatocyte Growth Factor; EC 2.7.10.1 / Proto-Oncogene Proteins c-met
  •  go-up   go-down


36. Jang KS, Song YS, Jang SH, Min KW, Na W, Jang SM, Jun YJ, Lee KH, Choi D, Paik SS: Clinicopathological significance of nuclear PTEN expression in colorectal adenocarcinoma. Histopathology; 2010 Jan;56(2):229-39
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological significance of nuclear PTEN expression in colorectal adenocarcinoma.
  • On univariate survival analysis, patients with PTEN- adenocarcinoma revealed a poor overall and disease-free survival (P = 0.030 and P = 0.046, respectively).
  • On multivariate analysis, a significant difference was observed in patients with stage II cancer that was not observed in other stages.
  • CONCLUSIONS: Nuclear PTEN expression gradually decrease during the normal-adenoma-adenocarcinoma-metastasis sequence, which suggests an important role for PTEN in carcinogenesis.
  • Moreover, loss of nuclear PTEN expression was a marker of poor clinical outcome in patients with stage II colorectal cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenomatous Polyps / metabolism. Cell Nucleus / metabolism. Colon / metabolism. Colorectal Neoplasms / metabolism. Intestinal Mucosa / metabolism. Lymph Nodes / metabolism. PTEN Phosphohydrolase / metabolism. Rectum / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20102402.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


37. Zaanan A, Cuilliere-Dartigues P, Guilloux A, Parc Y, Louvet C, de Gramont A, Tiret E, Dumont S, Gayet B, Validire P, Fléjou JF, Duval A, Praz F: Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann Oncol; 2010 Apr;21(4):772-80
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin.
  • BACKGROUND: The aim was to determine the values of p53 tumour expression and microsatellite instability (MSI) phenotype to predict benefit from adjuvant chemotherapy of colon cancer by 5-fluorouracil and leucovorin (FL) alone or with oxaliplatin (FOLFOX).
  • PATIENTS AND METHODS: This retrospective study included 233 unselected patients with stage III colon cancer treated by FL (n = 124) or FOLFOX (n = 109).
  • CONCLUSION: Our observations indicate that MSI status and p53 expression may influence the impact of oxaliplatin on adjuvant treatment of stage III colon cancer patients.

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19833818.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Tumor Suppressor Protein p53; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


38. Jensen SA, Vilmar A, Sørensen JB: Adjuvant chemotherapy in elderly patients (&gt;or=75 yr) completely resected for colon cancer stage III compared to younger patients: toxicity and prognosis. Med Oncol; 2006;23(4):521-31
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy in elderly patients (>or=75 yr) completely resected for colon cancer stage III compared to younger patients: toxicity and prognosis.
  • PURPOSE: To compare benefits and risks to adjuvant chemotherapy following complete resection of node-positive colon cancer stage III for patients aged >or=75 yr and younger.
  • CONCLUSIONS: Adjuvant 5-FU chemotherapy should be considered for elderly patients aged >or=75 yr in good performance at high risk of recurrence of colon carcinoma after resection.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Colonic Neoplasms / drug therapy

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17303911.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


39. Schetter AJ, Nguyen GH, Bowman ED, Mathé EA, Yuen ST, Hawkes JE, Croce CM, Leung SY, Harris CC: Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma. Clin Cancer Res; 2009 Sep 15;15(18):5878-87
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma.
  • PURPOSE: Inflammatory genes and microRNAs have roles in colon carcinogenesis; therefore, they may provide useful biomarkers for colon cancer.
  • This study examines the potential clinical utility of an inflammatory gene expression signature as a prognostic biomarker for colon cancer in addition to previously examined miR-21 expression.
  • EXPERIMENTAL DESIGN: Quantitative reverse transcriptase-PCR. was used to measure the expression of 23 inflammatory genes in colon adenocarcinomas and adjacent noncancerous tissues from 196 patients.
  • This association was strong for stage II cases (P = 0.002).
  • Both IRS and miR-21 expression were independently associated with cancer-specific mortality, including stage II patients alone.
  • CONCLUSION: IRS and miR-21 expression are independent predictors of colon cancer prognosis and may provide a clinically useful tool to identify high-risk patients.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Apr 1;101(7):2620-7 [12411307.001]
  • [Cites] Med Oncol. 2009;26 Suppl 1:13-7 [19148594.001]
  • [Cites] N Engl J Med. 2004 Apr 29;350(18):1828-37 [15115829.001]
  • [Cites] Lancet. 1987 Jun 6;1(8545):1303-6 [2884421.001]
  • [Cites] Lancet. 1990 Aug 11;336(8711):357-9 [1975343.001]
  • [Cites] N Engl J Med. 1990 Nov 1;323(18):1228-33 [2215606.001]
  • [Cites] Int J Cancer. 1999 Jun 21;84(3):326-30 [10371355.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3698-704 [10446984.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):828-33 [15944707.001]
  • [Cites] J Immunol. 2005 Nov 1;175(9):6177-89 [16237115.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1793-801 [16251535.001]
  • [Cites] Immunity. 2000 Nov;13(5):715-25 [11114383.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):854-62 [11241255.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2002 Jun;282(6):G1035-44 [12016129.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):143-8 [12518062.001]
  • [Cites] Nat Rev Immunol. 2003 Feb;3(2):133-46 [12563297.001]
  • [Cites] N Engl J Med. 2005 Dec 22;353(25):2654-66 [16371631.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):189-98 [16530703.001]
  • [Cites] Cancer Cell. 2006 Aug;10(2):99-111 [16904609.001]
  • [Cites] Science. 2006 Sep 29;313(5795):1960-4 [17008531.001]
  • [Cites] Cancer Biother Radiopharm. 2006 Oct;21(5):468-87 [17105420.001]
  • [Cites] Annu Rev Med. 2007;58:239-52 [17100552.001]
  • [Cites] Eur J Cancer. 2007 Mar;43(4):762-8 [17258448.001]
  • [Cites] J Clin Invest. 2007 May;117(5):1175-83 [17476347.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1330-3 [17496199.001]
  • [Cites] BMC Genomics. 2007;8:240 [17640343.001]
  • [Cites] J Natl Cancer Inst. 2007 Aug 15;99(16):1257-69 [17686824.001]
  • [Cites] Int J Cancer. 2007 Dec 1;121(11):2373-80 [17893866.001]
  • [Cites] PLoS One. 2007;2(10):e1020 [17925868.001]
  • [Cites] Nucleic Acids Res. 2008 Jan;36(Database issue):D149-53 [18158296.001]
  • [Cites] Cancer Metastasis Rev. 2008 Mar;27(1):11-8 [18066650.001]
  • [Cites] JAMA. 2008 Jan 30;299(4):425-36 [18230780.001]
  • [Cites] Lancet. 2008 Mar 1;371(9614):771-83 [18275997.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 Apr;8(4):595-604 [18402526.001]
  • [Cites] J Mol Biol. 2008 May 2;378(3):492-504 [18384814.001]
  • [Cites] Gastroenterology. 2008 May;134(5):1296-310 [18471507.001]
  • [Cites] Gut. 2008 Jun;57(6):772-9 [17965063.001]
  • [Cites] N Engl J Med. 2008 Jun 19;358(25):2664-5 [18565858.001]
  • [Cites] Carcinogenesis. 2008 Jun;29(6):1202-6 [18448485.001]
  • [Cites] Immunol Rev. 2008 Jun;223:114-31 [18613832.001]
  • [Cites] Ann Oncol. 2008 Oct;19(10):1734-41 [18550579.001]
  • [Cites] Clin Cancer Res. 2008 Nov 1;14(21):6735-41 [18980965.001]
  • [Cites] Genome Res. 2009 Jan;19(1):92-105 [18955434.001]
  • [Cites] J Immunol. 2003 Jul 15;171(2):600-7 [12847224.001]
  • (PMID = 19737943.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / Z99 CA999999; United States / Howard Hughes Medical Institute / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytokines; 0 / MIRN21 microRNA, human; 0 / MicroRNAs
  • [Other-IDs] NLM/ NIHMS125003; NLM/ PMC2745503
  •  go-up   go-down


40. Weissenberger C, Geissler M, Otto F, Barke A, Henne K, von Plehn G, Rein A, Muller C, Bartelt S, Henke M: Anemia and long-term outcome in adjuvant and neoadjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: the Freiburg experience (1989-2002). World J Gastroenterol; 2006 Mar 28;12(12):1849-58
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anemia and long-term outcome in adjuvant and neoadjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: the Freiburg experience (1989-2002).
  • METHODS: Two hundred and eighty-six patients with Union International Contre Cancer (UICC) stage II and III rectal adenocarcinomas, who underwent resection by conventional surgical techniques (low anterior or abdominoperineal resection), received either postoperative (n=233) or preoperative (n=53) radiochemotherapy from January 1989 until July 2002.
  • RESULTS: Anemia before radiochemotherapy was an independent prognostic factor for improved DFS (risk ratio 0.76, P=0.04) as well as stage, grading, R status (free radial margins), type of surgery, carcinoembryonic antigen (CEA) levels, and gender.
  • Stage, grading, R status (free radial margins), type of surgery, CEA levels, and gender have predictive value for the outcome of rectal cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Anemia / etiology. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Anemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1991 Mar 14;324(11):709-15 [1997835.001]
  • [Cites] Strahlenther Onkol. 2004 Jan;180(1):45-51 [14704844.001]
  • [Cites] Dis Colon Rectum. 1992 Nov;35(11):1057-65 [1425050.001]
  • [Cites] World J Surg. 1992 Sep-Oct;16(5):858-65 [1462620.001]
  • [Cites] Lancet. 1993 Feb 20;341(8843):457-60 [8094488.001]
  • [Cites] Dis Colon Rectum. 1993 Jun;36(6):564-72 [8500374.001]
  • [Cites] Dis Colon Rectum. 1994 Jan;37(1):73-87 [8287751.001]
  • [Cites] Am J Clin Oncol. 1995 Aug;18(4):277-81 [7625365.001]
  • [Cites] Int J Colorectal Dis. 1995;10(3):126-32 [7561427.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):305-11 [9069301.001]
  • [Cites] Br J Surg. 1997 Mar;84(3):352-7 [9117306.001]
  • [Cites] Anticancer Res. 1997 Mar-Apr;17(2B):1379-82 [9137502.001]
  • [Cites] Dis Colon Rectum. 1997 Jul;40(7):866-7 [9221868.001]
  • [Cites] Anticancer Res. 1997 Jul-Aug;17(4B):2935-8 [9329568.001]
  • [Cites] Strahlenther Onkol. 1998 Dec;174 Suppl 4:31-4 [9879345.001]
  • [Cites] Langenbecks Arch Surg. 1998 Dec;383(6):416-26 [9921941.001]
  • [Cites] Ann Surg. 1999 Oct;230(4):544-52; discussion 552-4 [10522724.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2412-8 [10561304.001]
  • [Cites] Cancer. 1999 Nov 15;86(10):1952-8 [10570418.001]
  • [Cites] Int J Biol Markers. 2000 Jan-Mar;15(1):51-5 [10763141.001]
  • [Cites] Int J Colorectal Dis. 2000 Feb;15(1):9-20 [10766086.001]
  • [Cites] Curr Opin Oncol. 2001 Jul;13(4):300-6 [11429489.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3895-902 [11559727.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] Br J Surg. 1984 Jan;71(1):12-6 [6689962.001]
  • [Cites] JAMA. 1990 Sep 19;264(11):1444-50 [2202842.001]
  • [Cites] N Engl J Med. 2001 Oct 11;345(15):1091-7 [11596588.001]
  • [Cites] Rev Invest Clin. 2001 Sep-Oct;53(5):388-95 [11795103.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1744-50 [11919230.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1751-8 [11919231.001]
  • [Cites] Eur J Cancer. 2002 May;38(7):919-36 [11978517.001]
  • [Cites] Am Surg. 2002 May;68(5):482-7 [12013294.001]
  • [Cites] Am J Surg. 2002 May;183(5):504-8 [12034381.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):386-96 [12243812.001]
  • [Cites] Eur J Cancer Care (Engl). 2002 Sep;11(3):166-72 [12296832.001]
  • [Cites] J Exp Clin Cancer Res. 2002 Sep;21(3):329-35 [12385573.001]
  • [Cites] Surg Clin North Am. 2002 Oct;82(5):1035-58 [12507208.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):549-57 [1548520.001]
  • (PMID = 16609990.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC4087509
  •  go-up   go-down


41. Schippinger W, Samonigg H, Schaberl-Moser R, Greil R, Thödtmann R, Tschmelitsch J, Jagoditsch M, Steger GG, Jakesz R, Herbst F, Hofbauer F, Rabl H, Wohlmuth P, Gnant M, Thaler J, Austrian Breast and Colorectal Cancer Study Group: A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. Br J Cancer; 2007 Oct 22;97(8):1021-7
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer.
  • The purpose of this trial was to investigate the efficacy of adjuvant chemotherapy with 5-fluorouracil (5-FU) and leucovorin (LV) in stage II colon cancer.
  • Patients with stage II colon cancer were randomised to either adjuvant chemotherapy with 5-FU/LV (100 mg m(-2) LV+450 mg m(-2) 5-FU weekly, weeks 1-6, in 8 weeks cycles x 7) or surveillance only.
  • In conclusion, results of this trial demonstrate a trend to a lower risk for relapse in patients treated with adjuvant 5-FU/LV for stage II colon cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Neoplasm Recurrence, Local / prevention & control

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3553-9 [10550154.001]
  • [Cites] Ann Surg. 2006 Oct;244(4):602-10 [16998369.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2912-9 [12885809.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2343-51 [15175436.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3395-407 [15199087.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3408-19 [15199089.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Biometrics. 1975 Mar;31(1):103-15 [1100130.001]
  • [Cites] J Natl Cancer Inst. 1988 Mar 2;80(1):30-6 [3276901.001]
  • [Cites] Arch Surg. 1989 Feb;124(2):180-2 [2916939.001]
  • [Cites] N Engl J Med. 1990 Feb 8;322(6):352-8 [2300087.001]
  • [Cites] J Clin Oncol. 1990 Sep;8(9):1466-75 [2202789.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1879-87 [8410113.001]
  • [Cites] Ann Intern Med. 1995 Mar 1;122(5):321-6 [7847642.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1349-55 [10334518.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1356-63 [10334519.001]
  • [Cites] Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66 [11602373.001]
  • (PMID = 17895886.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2360441
  •  go-up   go-down


42. Yokoi K, Tanaka N, Furukawa K, Seya T, Ohaki Y, Tajiri T: Case of adenosquamous carcinoma of the ascending colon. J Nippon Med Sch; 2008 Aug;75(4):242-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case of adenosquamous carcinoma of the ascending colon.
  • Adenocarcinoma accounts for most of the malignant tumors originating from the colon, whereas adenosquamous carcinoma is rare, accounting for about 0.1% of all colon cancers.
  • We present herein a case of adenosquamous carcinoma of the ascending colon.
  • A barium enema examination and lower gastrointestinal endoscopy showed a type 3 tumor in the ascending colon, and a biopsy confirmed the diagnosis of adenosquamous carcinoma.
  • Right hemicolectomy was performed, and the tumor was diagnosed as a stage III advanced colon cancer.
  • A search of Japanese literature over the past 25 years yielded 70 patients with adenosquamous carcinoma of the colon, and the clinicopathological features are discussed herein.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18781050.001).
  • [ISSN] 1345-4676
  • [Journal-full-title] Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
  • [ISO-abbreviation] J Nippon Med Sch
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


43. Chiang JM, Yeh CY, Changchien CR, Chen JS, Tang R, Chen JR: Mucinous adenocarcinoma showing different clinicopathological and molecular characteristics in relation to different colorectal cancer subgroups. Int J Colorectal Dis; 2010 Aug;25(8):941-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous adenocarcinoma showing different clinicopathological and molecular characteristics in relation to different colorectal cancer subgroups.
  • BACKGROUND: Mucinous adenocarcinoma (MAC) is frequently reported to be associated with patients of young-age sporadic colorectal cancer (YSCC) and hereditary nonpolyposis colorectal cancer (HNPCC).
  • RESULTS: Compared to non-MAC, MAC significantly showed higher frequencies of poor differentiation (32% vs. 8.2%, p = 0.001), advanced tumor stage (76% vs. 47%, p = 0.002), loss of mismatch repair protein (MMR) expression (74% vs. 44%, p = 0.023), and increased MUC2 expression (98% vs. 61%, p < 0.001).
  • MAC of HNPCC patients showed predominant right-sided colon involvement, whereas MAC of YSCC patients displayed predominance in the left colon (79% vs. 22%, p = 0.001).
  • Among the non-MAC counterparts, more differences were detectable including tumor stage, loss of MMR expression, and increased MUC1 expression.
  • Furthermore, both MAC and non-MAC of YSCC patients showed higher frequencies of advanced tumor stage (81% vs. 62%, p = 0.072).
  • CONCLUSIONS: Significantly different tumor localization was observed between mucinous YSCC (left colon predominance) and mucinous HNPCC (right colon predominance).
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Colorectal Neoplasms / classification. Colorectal Neoplasms / pathology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20532535.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Mucins
  •  go-up   go-down


44. Iarŭmov N, Toshev S, Angelov K, Lukanova Ts, Gribnev P, Sokolov M: [Multiple primary carcinomas of the colon and associated extracolonic primary malignant tumors]. Khirurgiia (Sofiia); 2007;(4):5-9
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multiple primary carcinomas of the colon and associated extracolonic primary malignant tumors].
  • Adenocarcinoma of the colon is the most common visceral cancer.
  • A total of 78 tumors were involved: 24 in the sigmoid, 12 transverse colon; four in the cecum; 30 in the rectum; 3 in the ascending and 5 in descending colon; 2 each in the bladder, prostate; two each in the breast, cervix, and one each in the skin, nasopharynx, lungs.
  • Survival of patients with synchronous carcinomas is not significantly different from survival of patients with same-stage solitary carcinomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18443527.001).
  • [ISSN] 0450-2167
  • [Journal-full-title] Khirurgii︠a︡
  • [ISO-abbreviation] Khirurgiia (Sofiia)
  • [Language] bul
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


45. Li D, Semba S, Wu M, Yokozaki H: Molecular pathological subclassification of mucinous adenocarcinoma of the colorectum. Pathol Int; 2005 Dec;55(12):766-74
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular pathological subclassification of mucinous adenocarcinoma of the colorectum.
  • The suppressor/p53-type tumors had a significant association with distal colon location (P = 0.019), venous invasion (P = 0.002), extent of lymph node metastasis (P = 0.007) and higher tumor stage (P = 0.018).
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Colorectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16287491.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / Gastric Mucins; 0 / Ki-67 Antigen; 0 / MLH1 protein, human; 0 / Nuclear Proteins; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


46. Paik SS, Jang SM, Jang KS, Lee KH, Choi D, Jang SJ: Leptin expression correlates with favorable clinicopathologic phenotype and better prognosis in colorectal adenocarcinoma. Ann Surg Oncol; 2009 Feb;16(2):297-303
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptin expression correlates with favorable clinicopathologic phenotype and better prognosis in colorectal adenocarcinoma.
  • We investigated leptin expression in normal and neoplastic colorectal tissues and its association with clinicopathological features and clinical outcome in colorectal adenocarcinoma patients.
  • Leptin expression was evaluated on the tissue microarray of 44 normal colon mucosal tissues, 44 adenomatous polyps, and 437 colorectal adenocarcinomas by immunohistochemistry.
  • Interestingly, leptin expression was correlated with favorable tumor features in depth of invasion (p = 0.033), lymph node metastasis (p = 0.019), American Joint Committee on Cancer (AJCC) and Dukes' stage (p = 0.021 and p = 0.005, respectively), differentiation (p = 0.010), and lymphatic invasion (p = 0.003).
  • In univariate survival analysis, patients with leptin-positive adenocarcinoma revealed better overall and disease-free survivals (p = 0.032 and p = 0.004, respectively, log-rank test).
  • We conclude that leptin was gradually expressed during the normal-adenoma-adenocarcinoma sequence, suggesting an association in colorectal carcinogenesis.
  • [MeSH-major] Adenocarcinoma / metabolism. Colorectal Neoplasms / metabolism. Leptin / metabolism
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Adenomatous Polyps / metabolism. Adenomatous Polyps / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Child. Colon / metabolism. Colon / pathology. Female. Humans. Immunoenzyme Techniques. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Phenotype. Survival Rate. Tissue Array Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19050975.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Leptin
  •  go-up   go-down


47. Ginty F, Adak S, Can A, Gerdes M, Larsen M, Cline H, Filkins R, Pang Z, Li Q, Montalto MC: The relative distribution of membranous and cytoplasmic met is a prognostic indicator in stage I and II colon cancer. Clin Cancer Res; 2008 Jun 15;14(12):3814-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relative distribution of membranous and cytoplasmic met is a prognostic indicator in stage I and II colon cancer.
  • PURPOSE: The association hepatocyte growth factor receptor (Met) tyrosine kinase with prognosis and survival in colon cancer is unclear, due in part to the limitation of detection methods used.
  • EXPERIMENTAL DESIGN: Fluorescent-based IHC for Met was done in 583 colon cancer patients in a tissue microarray format.
  • RESULTS: In crossvalidated and univariate Cox analysis, the membrane relative to cytoplasm Met score was a significant predictor of survival in stage I (hazard ratio, 0.16; P = 0.006) and in stage II patients (hazard ratio, 0.34; P < or = 0.0005).
  • Met in the membrane alone was not a significant predictor of outcome in all patients or within stage.
  • CONCLUSIONS: These data indicate that the relative subcellular distribution of Met, as measured by novel automated image analysis, may be a valuable biomarker for estimating colon cancer prognosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Cell Membrane / metabolism. Colonic Neoplasms / diagnosis. Colonic Neoplasms / pathology. Cytoplasm / metabolism. Proto-Oncogene Proteins / metabolism. Receptors, Growth Factor / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18559601.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins; 0 / Receptors, Growth Factor; EC 2.7.10.1 / MET protein, human; EC 2.7.10.1 / Proto-Oncogene Proteins c-met
  •  go-up   go-down


48. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, Cisar L, Labianca R, Cunningham D, Van Cutsem E, Bosman F: Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol; 2010 Jan 20;28(3):466-74
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.
  • We took advantage of PETACC-3, an adjuvant trial with 3,278 patients with stage II to III colon cancer, to evaluate the prognostic value of KRAS and BRAF tumor mutation status in this setting.
  • RESULTS: KRAS and BRAF tumor mutation rates were 37.0% and 7.9%, respectively, and were not significantly different according to tumor stage.
  • In a multivariate analysis containing stage, tumor site, nodal status, sex, age, grade, and microsatellite instability (MSI) status, KRAS mutation was associated with grade (P = .0016), while BRAF mutation was significantly associated with female sex (P = .017), and highly significantly associated with right-sided tumors, older age, high grade, and MSI-high tumors (all P < 10(-4)).
  • CONCLUSION: In stage II-III colon cancer, the KRAS mutation status does not have major prognostic value.
  • [MeSH-major] Adenocarcinoma / genetics. Colonic Neoplasms / genetics. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins B-raf / genetics. ras Proteins / genetics

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20008640.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


49. Dahl O, Fluge Ø, Carlsen E, Wiig JN, Myrvold HE, Vonen B, Podhorny N, Bjerkeset O, Eide TJ, Halvorsen TB, Tveit KM, Norwegian Gastrointestinal Cancer Group: Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group. Acta Oncol; 2009;48(3):368-76
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group.
  • BACKGROUND: The recommendation of adjuvant chemotherapy for colon cancer with lymph node metastases, based on two studies from USA, was reluctantly accepted by Norwegian medical doctors.
  • MATERIAL AND METHODS: Four hundred and twenty five patients with operable colon and rectum cancer, Stage II and III (Dukes' stage B and C), were from January 1993 to October 1996, included in a randomised multicentre trial in Norway.
  • There was no difference between the two groups when analysed for colon and rectum separately.
  • However, the subgroup of colon cancer with stage III exhibited a statistically significant difference both for DFS, 58% vs. 37% (p=0.012) and CSS, 65% vs. 47% (p=0.032) in favour of adjuvant chemotherapy.
  • CONCLUSIONS: Colon cancer patients with lymph node metastases benefit from adjuvant chemotherapy with 5-FU/Lev with acceptable toxicity.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Antirheumatic Agents / therapeutic use. Colonic Neoplasms / drug therapy. Fluorouracil / therapeutic use. Levamisole / therapeutic use. Rectal Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19242829.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antirheumatic Agents; 2880D3468G / Levamisole; U3P01618RT / Fluorouracil
  •  go-up   go-down


50. Abd El-Hameed A: Survivin expression in colorectal adenocarcinoma using tissue microarray. J Egypt Natl Canc Inst; 2005 Mar;17(1):42-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survivin expression in colorectal adenocarcinoma using tissue microarray.
  • This study examined the expression, and potential prognostic value of survivin in colorectal adenocarcinoma (CRC) on tissue microarray (TMA) sections.
  • MATERIAL AND METHODS: Two-hundred and eighty cases of colorectal adenocarcinoma were arrayed.
  • There was no correlation between survivin immunoreactivity and age, sex, tumor site, tumor size, histopathologic subtype, tumor grade and clinical stage (p >0.05).
  • The 5-year disease free survival (DFS) for patients with survivin positive colorectal adenocarcinoma was significantly lower than that for patients with survivin negative tumors (46% versus 68.7%, p=0.001).
  • CONCLUSION: Survivin expression in colorectal adenocarcinoma provides an important prognostic parameter and targeted antagonists of survivin may be beneficial as apoptosis-based therapy for colon cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Colorectal Neoplasms / diagnosis. Microtubule-Associated Proteins / analysis. Neoplasm Proteins / analysis. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16353082.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


51. Bosch Roig CE, Roselló-Sastre E, Alonso Hernández S, Almenar Cubells D, Grau Cardona E, Camarasa Lillo N, Bautista D, Molins Palau C: Prognostic value of the detection of lymph node micrometastases in colon cancer. Clin Transl Oncol; 2008 Sep;10(9):572-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of the detection of lymph node micrometastases in colon cancer.
  • INTRODUCTION AND OBJECTIVES: A study is made of the clinical repercussions of occult metastases-micrometastases (MMs+)-or isolated tumour cells (ITCs+) in the lymph nodes of patients with stage IIA and IIB colon adenocarcinoma initially considered as corresponding to N0.
  • MATERIAL AND METHODS: A retrospective study of 39 patients with stage IIA and IIB (T3-T4 N0 M0) colon adenocarcinoma, subjected to similar surgical and adjuvant chemotherapy treatment, with long and careful follow-up (minimum: 5 years, mean: 81.7 months) was performed on their previously resected lymph nodes, with the aid of new histological and immunohistochemical (cytokeratin) sections, in order to detect MMs or ITCs.
  • We encourage a detailed histological study of lymph nodes resected in patients with deep penetrating colon tumours in order to assure a pN0 status.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma, Mucinous / secondary. Colonic Neoplasms / blood. Colonic Neoplasms / pathology. Lymph Nodes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18796374.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


52. Bilimoria KY, Palis B, Stewart AK, Bentrem DJ, Freel AC, Sigurdson ER, Talamonti MS, Ko CY: Impact of tumor location on nodal evaluation for colon cancer. Dis Colon Rectum; 2008 Feb;51(2):154-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of tumor location on nodal evaluation for colon cancer.
  • PURPOSE: Adequate lymph node evaluation is important to stage colon cancers and make adjuvant treatment decisions.
  • Our objective was to assess differences in the adequacy of nodal evaluation for right vs. left colon cancers.
  • METHODS: From the National Cancer Data Base (1998-2004), 142,009 N0M0 colon cancer patients were identified.
  • Patients were more likely to have >or= 12 nodes identified for right and left colon cancers at high-volume hospitals.
  • Survival was better with examination of >or= 12 nodes for right and left colon cancers (P < 0.0001).
  • CONCLUSIONS: Evaluating >or= 12 nodes for right and left colon cancers is a feasible, clinically relevant, and modifiable factor that will likely improve patient outcomes.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Lymph Nodes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18172729.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


53. Chang GJ, Gonzalez RJ, Skibber JM, Eng C, Das P, Rodriguez-Bigas MA: A twenty-year experience with adenocarcinoma of the anal canal. Dis Colon Rectum; 2009 Aug;52(8):1375-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A twenty-year experience with adenocarcinoma of the anal canal.
  • PURPOSE: Adenocarcinoma of the anal canal is a rare malignancy with limited data regarding treatment and outcomes.
  • The purpose of this study is to evaluate disease control and survival outcomes in patients with adenocarcinoma of the anal canal.
  • METHODS: A retrospective consecutive cohort study of all patients in whom adenocarcinoma of the anal canal was diagnosed between 1983 and 2004 was performed.
  • RESULTS: Thirty-four patients were identified; six underwent palliative treatment (Stage IV, n = 4; poor performance, n = 2).
  • CONCLUSION: Combined modality treatment with radical surgical resection improves survival among patients with adenocarcinoma of the anal canal, but a high risk for distant failure emphasizes the need for effective adjuvant therapeutic regimens.
  • [MeSH-major] Adenocarcinoma / epidemiology. Anus Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19617747.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Kalady MF, Sanchez JA, Manilich E, Hammel J, Casey G, Church JM: Divergent oncogenic changes influence survival differences between colon and rectal adenocarcinomas. Dis Colon Rectum; 2009 Jun;52(6):1039-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Divergent oncogenic changes influence survival differences between colon and rectal adenocarcinomas.
  • This study evaluated the disparity in neoplastic changes between colon and rectal cancers.
  • METHODS: A clinic-based colorectal frozen tumor bank at a single institution was queried for colon and rectal adenocarcinomas.
  • RESULTS: The 268 patients with colon cancer and 89 with rectal cancer were similar in gender, tumor size, stage, and differentiation.
  • Colon cancers had a higher incidence of microsatellite instability (27 percent) and methylator phenotype (28 percent) compared with rectal cancers (7 percent, 3 percent, respectively; P < 0.001).
  • Although KRAS mutation rate was similar, colon cancers had a higher incidence of BRAF mutations (16.7 percent vs. 0 percent; P < 0.001).
  • Despite overall differences in outcome between colon and rectal cancers, no significant difference in survival existed when similar molecular phenotypes were compared across anatomic sites.
  • CONCLUSIONS: Although colon cancers are molecularly heterogeneous, rectal cancers arise mostly via a single neoplastic pathway.
  • Genetic and molecular differences influence prognosis more than anatomic location and suggest that oncogenic pathways contribute to survival differences between colon and rectal cancers.
  • [MeSH-major] Adenocarcinoma / pathology. Colonic Neoplasms / pathology. Rectal Neoplasms / pathology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19581844.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


55. Kontos CK, Papadopoulos IN, Fragoulis EG, Scorilas A: Quantitative expression analysis and prognostic significance of L-DOPA decarboxylase in colorectal adenocarcinoma. Br J Cancer; 2010 Apr 27;102(9):1384-90
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative expression analysis and prognostic significance of L-DOPA decarboxylase in colorectal adenocarcinoma.
  • The aim of this study was to investigate the mRNA expression levels of the DDC gene and to evaluate its clinical utility in tissues with colorectal adenocarcinoma.
  • METHODS: Total RNA was isolated from colorectal adenocarcinoma tissues of 95 patients.
  • High DDC mRNA expression levels were found in well-differentiated and Dukes' stage A and B tumours.
  • CONCLUSIONS: The results of the study suggest that DDC mRNA expression may be regarded as a novel potential tissue biomarker in colorectal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Colorectal Neoplasms / genetics. Dopa Decarboxylase / genetics. Gene Expression Regulation, Neoplastic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood Cells Mol Dis. 2009 Jan-Feb;42(1):92-8 [19041269.001]
  • [Cites] Neurochem Res. 2009 Jun;34(6):1089-100 [19005753.001]
  • [Cites] Nat Rev Cancer. 2009 Jul;9(7):489-99 [19536109.001]
  • [Cites] Mol Cell Biochem. 1990 May 10;94(2):147-56 [2374548.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):6068-74 [2168288.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2161-5 [2006153.001]
  • [Cites] Biochemistry. 1992 Mar 3;31(8):2229-38 [1540578.001]
  • [Cites] Br J Cancer. 1992 Jul;66(1):148-54 [1379057.001]
  • [Cites] J Natl Cancer Inst. 1992 Oct 21;84(20):1572-5 [1404450.001]
  • [Cites] Biochemistry. 1992 Nov 24;31(46):11546-50 [1445888.001]
  • [Cites] Lancet. 1992 Dec 5;340(8832):1369-73 [1360088.001]
  • [Cites] N Engl J Med. 1994 Jul 28;331(4):213-21 [8015568.001]
  • [Cites] Biochem Pharmacol. 1995 Sep 7;50(6):845-50 [7575647.001]
  • [Cites] J Neurochem. 1995 Dec;65(6):2409-16 [7595534.001]
  • [Cites] Neurochem Res. 1996 Sep;21(9):1075-87 [8897471.001]
  • [Cites] N Engl J Med. 1996 Dec 5;335(23):1727-32 [8929264.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):427-33 [9469325.001]
  • [Cites] Gastroenterology. 1998 Jun;114(6):1180-7 [9609754.001]
  • [Cites] Dis Colon Rectum. 1998 Jun;41(6):755-60 [9645744.001]
  • [Cites] Br J Cancer. 1999 Jan;79(2):191-203 [9888457.001]
  • [Cites] Clin Biochem. 2008 Oct;41(14-15):1140-9 [18586020.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] J Neuroimmunol. 2009 Nov 30;216(1-2):51-8 [19800137.001]
  • [Cites] Eur J Cancer. 2010 Mar;46(4):765-81 [20116997.001]
  • [Cites] Biochem Pharmacol. 1999 Jun 15;57(12):1341-4 [10353253.001]
  • [Cites] Am J Pathol. 1999 Jul;155(1):17-21 [10393831.001]
  • [Cites] Neurochem Res. 2004 Oct;29(10):1817-23 [15532536.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7252-9 [15534099.001]
  • [Cites] CA Cancer J Clin. 2004 Nov-Dec;54(6):295-308 [15537574.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):609-18 [15659508.001]
  • [Cites] Br J Cancer. 2005 Feb 14;92(3):434-44 [15668707.001]
  • [Cites] J Gastrointest Surg. 2005 Mar;9(3):336-42 [15749593.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2606-11 [15814640.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 12;102(28):9901-6 [15998737.001]
  • [Cites] Neurochem Res. 2005 May;30(5):641-9 [16176068.001]
  • [Cites] Eur J Cancer. 2005 Sep;41(14):2060-70 [16125380.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7518-28 [16172461.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 2005 Nov;372(3):228-35 [16247607.001]
  • [Cites] J Histochem Cytochem. 2006 Aug;54(8):863-75 [16517981.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5313-27 [17060676.001]
  • [Cites] Hum Pathol. 2007 Jan;38(1):161-70 [16997353.001]
  • [Cites] Mol Cancer. 2007;6:38 [17553164.001]
  • [Cites] Dig Dis Sci. 2008 May;53(5):1289-96 [17934851.001]
  • [Cites] Gut. 2008 Jul;57(7):941-50 [18364437.001]
  • [Cites] N Engl J Med. 2000 Jan 13;342(2):69-77 [10631274.001]
  • [Cites] Dig Surg. 2000;17(3):209-15 [10867451.001]
  • [Cites] N Engl J Med. 2000 Jul 20;343(3):162-8 [10900274.001]
  • [Cites] Clin Cancer Res. 2000 Nov;6(11):4365-72 [11106255.001]
  • [Cites] Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66 [11602373.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):153-6 [11668491.001]
  • [Cites] Int J Cancer. 2002 Jan 1;97(1):72-81 [11774246.001]
  • [Cites] Methods. 2001 Dec;25(4):386-401 [11846608.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Br J Cancer. 2002 Sep 9;87(6):630-4 [12237773.001]
  • [Cites] Eur J Cancer. 2003 Apr;39(6):718-27 [12651195.001]
  • [Cites] Neurochem Res. 2003 Jun;28(6):797-803 [12718431.001]
  • [Cites] Biochem J. 2003 Oct 15;375(Pt 2):373-83 [12864730.001]
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):529-36 [14752076.001]
  • [Cites] Br J Cancer. 2004 Feb 9;90(3):665-71 [14760382.001]
  • [Cites] Diagn Mol Pathol. 2004 Sep;13(3):135-43 [15322424.001]
  • [Cites] Proc Natl Acad Sci U S A. 1972 Feb;69(2):343-7 [4536745.001]
  • [Cites] Endocrinology. 1983 Apr;112(4):1524-9 [6339207.001]
  • [Cites] Biochemistry. 1983 Dec 20;22(26):6058-63 [6661425.001]
  • [Cites] Cancer. 1986 May 1;57(9):1866-70 [3485470.001]
  • [Cites] Cancer Res. 1988 Jul 15;48(14):4078-82 [3383200.001]
  • [Cites] Biochem Biophys Res Commun. 1989 Nov 15;164(3):1024-30 [2590185.001]
  • [CommentIn] Br J Cancer. 2010 Oct 26;103(9):1475-6 [20859286.001]
  • (PMID = 20424616.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 4.1.1.- / Dopa Decarboxylase
  • [Other-IDs] NLM/ PMC2865762
  •  go-up   go-down


56. Kuebler JP, Colangelo L, O'Connell MJ, Smith RE, Yothers G, Begovic M, Robinson B, Seay TE, Wolmark N: Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis. Cancer; 2007 Nov 1;110(9):1945-50
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis.
  • BACKGROUND: Cases of severe gastrointestinal toxicity were monitored prospectively during NSABP C-07, a randomized clinical trial of adjuvant therapy for patients with stage II/III colon cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Colonic Diseases / chemically induced. Colonic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17853393.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00004931
  • [Grant] United States / NCI NIH HHS / CA / U10-CA-12027; United States / NCI NIH HHS / CA / U10-CA-37377; United States / NCI NIH HHS / CA / U10-CA-69651; United States / NCI NIH HHS / CA / U10-CA-69974
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


57. Jestin P, Påhlman L, Glimelius B, Gunnarsson U: Cancer staging and survival in colon cancer is dependent on the quality of the pathologists' specimen examination. Eur J Cancer; 2005 Sep;41(14):2071-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer staging and survival in colon cancer is dependent on the quality of the pathologists' specimen examination.
  • Correct staging of colon cancer is decisive regarding further oncological treatment, surveillance and prediction of long-term survival.
  • Data from the colon cancer register (1997-2002) of the Uppsala/Orebro, Sweden, health care region were analysed and the seven pathology departments in this region were compared.
  • Included were 3735 patients who had undergone resection of a colon cancer.
  • Survival in stage II was lower when fewer than 12 nodes were examined or when the number of nodes sampled was not given (P = 0.001, log-rank test).
  • In stage III, those with at the most 3 nodes positive (N1) had a better survival than those with 4 or more nodes positive (N2) (P < 0.001, log-rank test).
  • An index of metastases (IM), derived from the number of nodes with metastases divided by the number of nodes examined, was calculated for stage III tumours.
  • Examination of 12 nodes is necessary to assure stage III cases with the median IM (0.32), whereas 20 nodes are necessary to assure 90% of cases with the lower quartile of IM (0.16).
  • The prognostic information of the IM was higher than that of the N-stage.
  • An index of metastases (IM) is a possible basis for guidance in the choice of adjuvant treatments that appears superior to that of N-stage.
  • [MeSH-major] Adenocarcinoma / pathology. Colonic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16125926.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


58. Törnroos A, Garvin S, Olsson H: The number of identified lymph node metastases increases continuously with increased total lymph node recovery in pT3 colon cancer. Acta Oncol; 2009;48(8):1152-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The number of identified lymph node metastases increases continuously with increased total lymph node recovery in pT3 colon cancer.
  • BACKGROUND. The positive correlation between the number of recovered benign lymph nodes and patient prognosis is well established for stage II colon cancer patients.
  • One theory explaining this correlation focuses on potential understaging of cancer specimen, implying that a specimen with few examined lymph nodes is likely to be assigned a lower N-stage than the correct one.
  • This study aims to investigate the association between the total lymph node harvest and the number of lymph node metastases in colon cancer specimen.
  • We studied the original pathology reports of 649 patients diagnosed with T3 adenocarcinoma of the colon at the Department of Clinical Pathology and Genetics at Linköping University Hospital, Linköping, Sweden between the years 2000 and 2008.
  • Rather than focusing on a recommended minimum number of nodes, efforts should be shifted towards developing methods assuring that colon cancer specimen are dissected in a standardized way that optimizes the lymph node harvest.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Lymph Node Excision. Lymph Nodes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19863223.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


59. Fishman DA, Cohen L, Blank SV, Shulman L, Singh D, Bozorgi K, Tamura R, Timor-Tritsch I, Schwartz PE: The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer. Am J Obstet Gynecol; 2005 Apr;192(4):1214-21; discussion 1221-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer.
  • OBJECTIVE: Epithelial ovarian cancer kills more women than all other gynecologic malignancies combined because of our inability to detect early-stage disease.
  • Ultrasonography has demonstrated usefulness in the detection of ovarian cancer in asymptomatic women, but its value for the detection of early-stage epithelial ovarian cancer in women of increased risk is uncertain.
  • We examined the usefulness of sonography in the detection of early-stage epithelial ovarian cancer in asymptomatic high-risk women who participated in the National Ovarian Cancer Early Detection Program.
  • Increased risk includes women with at least 1 affected first-degree relative with ovarian cancer; a personal history of breast, ovarian, or colon cancer; > or =1 affected first- and second-degree relatives with breast and or ovarian cancer; inheritance of a breast cancer mutation from an affected family member, or membership within a recognized cancer syndrome.
  • The detected malignancies were fallopian tube carcinoma (stage IIIC; n = 4 women), primary peritoneal carcinoma (n = 4 women; stage IIIA, 1 woman; stage IIIB, 2 women; stage IIIC, 1 woman), epithelial ovarian cancer (stages IIIA and IIIB; n = 2 women), and endometrial adenocarcinoma (stage IA; n = 2 women).
  • A total of 184 women with genetic predisposition (breast cancer positive) have undergone a prophylactic bilateral salpingo-oophorectomy; 23% of these procedures found atypical hyperplasia, and unexpectedly, 2 women (1%) were found to have stage III (A and B) primary peritoneal carcinoma.
  • CONCLUSION: This study demonstrates the limited value of diagnostic ultrasound examination as an independent modality for the detection of early-stage epithelial ovarian cancer in asymptomatic women who are at increased risk for disease.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15846205.001).
  • [ISSN] 0002-9378
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA83639; United States / NCI NIH HHS / CA / R01 CA01015; United States / NCI NIH HHS / CA / R01 CA82562; United States / NCI NIH HHS / CA / R01 CA89503; United States / NCI NIH HHS / CA / UO1CA85133
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


60. Abdelrazeq AS, Scott N, Thorn C, Verbeke CS, Ambrose NS, Botterill ID, Jayne DG: The impact of spontaneous tumour perforation on outcome following colon cancer surgery. Colorectal Dis; 2008 Oct;10(8):775-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of spontaneous tumour perforation on outcome following colon cancer surgery.
  • OBJECTIVE: The impact of spontaneous tumour perforation on survival following surgery for colon cancer is unclear.
  • This study compares survival outcomes for patients with perforated colonic cancer with stage-matched nonperforated cancer.
  • METHOD: A prospective histological database was searched for all patients undergoing resection for adenocarcinoma of the colon between 1996 and 2002.
  • RESULTS: Of 960 patients identified, 52 patients had spontaneous tumour perforation and 82 patients served as the T-stage matched control group.
  • CONCLUSION: Both perforated and nonperforated T4 colon cancers have a poor prognosis.
  • Rather, it is the advanced oncological stage at which perforated cancers present that determines outcome.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Cause of Death. Colonic Neoplasms / mortality. Colonic Neoplasms / surgery. Intestinal Perforation / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18266887.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


61. Trautmann K, Terdiman JP, French AJ, Roydasgupta R, Sein N, Kakar S, Fridlyand J, Snijders AM, Albertson DG, Thibodeau SN, Waldman FM: Chromosomal instability in microsatellite-unstable and stable colon cancer. Clin Cancer Res; 2006 Nov 1;12(21):6379-85
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal instability in microsatellite-unstable and stable colon cancer.
  • PURPOSE: The genomic instability in colon cancer can be divided into at least two major types, microsatellite instability (MSI) or chromosomal instability (CIN).
  • The aim of this study was to identify chromosomal alterations at high resolution in sporadic colon cancers with high-level microsatellite instability (MSI-H) and to compare them to those present in a set of matched microsatellite stable (MSS) tumors.
  • EXPERIMENTAL DESIGN: Array-based comparative genomic hybridization was used to analyze a set of 23 sporadic MSI-H and 23 MSS colon cancers matched for location, gender, stage, and age.
  • RESULTS: MSI and MSS colon cancers differed significantly with respect to frequency and type of chromosomal alterations.
  • CONCLUSION: MSI and CIN are not mutually exclusive forms of genomic instability in sporadic colon cancer, with MSI tumors also showing varying degrees of CIN.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosomal Instability. Colonic Neoplasms / genetics. Microsatellite Instability

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17085649.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA92374
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


62. Olszewski WL, Kubicka U, Tarnowski W, Bielecki K, Ziolkowska A, Wesolowska A: Activation of human peritoneal immune cells in early stages of gastric and colon cancer. Surgery; 2007 Feb;141(2):212-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of human peritoneal immune cells in early stages of gastric and colon cancer.
  • We investigated mobilization of immune cells in peritoneal fluid of gastric and colon cancer, phenotypes and level of activation of recruited cells, and concentration of cellular and peritoneal fluid cytokines.
  • METHODS: Peritoneal cells (PCs) were obtained intraoperatively by peritoneal lavage from 18 patients with adenocarcinoma of the stomach and 32 patients with adenocarcinoma of the colon (all were stage T2N0M0) and 52 patients who underwent elective cholecystectomy as control subjects.
  • In the patients with colon cancer, the percentage of CD68+ macrophages was 1.2 times, of CD14+ monocytes was 2.3 times, and of CD15+ granulocytes was 3 times greater than in control patients (all P < .05).
  • When the cancer groups were compared, there was evidently more activated myeloid- and cytokine-producing PC in the patients with colon cancer than in patients with gastric cancer.
  • CONCLUSION: Patients with T2N0M0 colon cancer and to lesser extent gastric cancer evoke a slight but measurable mobilization and activation of PCs.
  • [MeSH-major] Adenocarcinoma / immunology. Colonic Neoplasms / immunology. Leukocytes / physiology. Peritoneal Cavity / pathology. Stomach Neoplasms / immunology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17263978.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Cytokines; 0 / Endotoxins
  •  go-up   go-down


63. Fang YJ, Lu ZH, Wang F, Wu XJ, Li LR, Zhang LY, Pan ZZ, Wan DS: Prognostic impact of ERβ and MMP7 expression on overall survival in colon cancer. Tumour Biol; 2010 Dec;31(6):651-8
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of ERβ and MMP7 expression on overall survival in colon cancer.
  • Estrogen receptor beta (ERβ) is the most highly expressed protein in patients with colon cancer.
  • We have previously shown that endocrine therapy can inhibit MMP7 expression in colon cancer cells.
  • In this study, we aim to identify the prognostic effects and correlation of ERβ and MMP7 in the context of colon cancer.
  • ERβ and MMP7 levels were assessed by immunohistochemistry in normal mucosa and tumoral tissues from 423 patients with stage I-III colon cancer.
  • In the subset of patients with high expression levels of tumoral nuclear ERβ, high expression of MMP7 was related to OS and CSS among colon cancer patients with high expression of ERβ.
  • In conclusion, our results suggest that low expression of ERβ was a risk factor in colon cancer, and high expression of MMP7 was an independent prognostic factor of ERβ-positive patients with colon cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / mortality. Colonic Neoplasms / metabolism. Colonic Neoplasms / mortality. Estrogen Receptor beta / metabolism. Matrix Metalloproteinase 7 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20680712.001).
  • [ISSN] 1423-0380
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Estrogen Receptor beta; EC 3.4.24.23 / Matrix Metalloproteinase 7
  •  go-up   go-down


64. Wu CY, Lee WH, Wang JY, Chiang H, Chang JL, Tsai WC, Sheu LF, Jin JS: Tissue microarray-determined expression profiles of cyclooxygenase-2 in colorectal adenocarcinoma: association with clinicopathological parameters. Chin J Physiol; 2006 Dec 31;49(6):298-304
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue microarray-determined expression profiles of cyclooxygenase-2 in colorectal adenocarcinoma: association with clinicopathological parameters.
  • Our purpose was to quantitate COX-2 expression in colorectal cancers using tissue microarray analysis and look for an association with clinicopathological stage.
  • All colorectal adenocarcinomas showed significant immunohistochemical expression of COX-2 when compared to normal colon epithelia.
  • The COX-2 immunostaining score correlated significantly with T stage (P < 0.05) but not with N or M stage.
  • The positive expression rates of CK20 were 97% for well-differentiated, 94% for moderately differentiated, and 65% for poorly differentiated colorectal adenocarcinomas, suggesting that CK20 may not be an effective discriminator between poorly differentiated colorectal adenocarcinoma and metastatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / enzymology. Colorectal Neoplasms / enzymology. Cyclooxygenase 2 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17357536.001).
  • [ISSN] 0304-4920
  • [Journal-full-title] The Chinese journal of physiology
  • [ISO-abbreviation] Chin J Physiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


65. Linebarger JH, Mathiason MA, Kallies KJ, Shapiro SB: Does obesity impact lymph node retrieval in colon cancer surgery? Am J Surg; 2010 Oct;200(4):478-82
Genetic Alliance. consumer health - Obesity.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does obesity impact lymph node retrieval in colon cancer surgery?
  • BACKGROUND: Evaluation of lymph nodes is important for the optimal treatment of colon adenocarcinoma.
  • We hypothesized that lymph node retrieval in colon cancer resection would be reduced in obese patients.
  • METHODS: Patients undergoing resection for colon adenocarcinoma diagnosed from 2000 to 2007 were reviewed retrospectively and stratified by body mass index (BMI).
  • Adequacy of node harvest differed by stage (P = .007), left-sided versus right-sided resections (P = .001), and pathology technician (P = .001).
  • [MeSH-major] Adenocarcinoma / surgery. Colectomy / methods. Colonic Neoplasms / surgery. Lymph Node Excision / methods. Obesity, Morbid / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20887841.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Grillo-Ruggieri F, Mantello G, Berardi R, Cardinali M, Fenu F, Iovini G, Montisci M, Fabbietti L, Marmorale C, Guerrieri M, Saba V, Bearzi I, Mattioli R, Bonsignori M, Cascinu S: Mucinous rectal adenocarcinoma can be associated to tumor downstaging after preoperative chemoradiotherapy. Dis Colon Rectum; 2007 Oct;50(10):1594-603
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous rectal adenocarcinoma can be associated to tumor downstaging after preoperative chemoradiotherapy.
  • PURPOSE: The aim of this study was to evaluate downstaging as primary end point, and progression-free survival and overall survival as secondary end points, in rectal adenocarcinoma patients treated with preoperative chemoradiation.
  • METHODS: One hundred and thirty-six extraperitoneal adenocarcinoma patients (33 low rectum T2, 74 T3, 29 T4 [without sacral invasion], 25 with mucinous subtype) were treated with posterior pelvis preoperative radiotherapy (5040 cGy total dose, 180 cGy/fr, 5 fr/w, 10-15 MV linac X-rays) and concomitant 5-fluorouracil-based chemotherapy.
  • After 6 to 8 weeks patients underwent surgery and prechemoradiation clinical stage was compared with pathologic stage to evaluate downstaging in each patient.
  • There were no significant differences in overall survival and progression-free survival between adenocarcinoma and mucinous subtype.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / therapy. Rectal Neoplasms / pathology. Rectal Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17846841.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


67. Forssell J, Oberg A, Henriksson ML, Stenling R, Jung A, Palmqvist R: High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res; 2007 Mar 1;13(5):1472-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High macrophage infiltration along the tumor front correlates with improved survival in colon cancer.
  • RESULTS: Including all patients, regardless of surgical outcome and localization, survival increased incrementally with CD68TF(Mean) infiltration grade (P = 0.0001) but not in curatively resected colon cancers (P = 0.28).
  • A high hotspot score conferred a highly significant survival advantage also in curatively resected colon cancer cases (n = 199, P = 0.0002) but not in rectal cancers.
  • CD68TF(Hotspot) high turned out as an independent prognostic marker for colon cancer in multivariate analyses including gender, age, localization, grade, stage, tumor type, and lymphocytes at the tumor front, conferring a relative risk of 0.49 (P = 0.007).
  • In vitro coculture experiments, using phorbol 12-myristate 13-acetate-activated U937 cells as macrophage model, revealed that a high ratio of macrophages to colon cancer cells inhibited cancer cell growth.
  • CONCLUSIONS: In conclusion, our data indicate that a dense macrophage infiltration at the tumor front positively influences prognosis in colon cancer and that the degree of cell-to-cell contact may influence the balance between protumorigenic and antitumorigenic properties of macrophages.
  • [MeSH-major] Adenocarcinoma / immunology. Adenocarcinoma / mortality. Colorectal Neoplasms / immunology. Colorectal Neoplasms / mortality. Macrophages / immunology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17332291.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human
  •  go-up   go-down


68. Mielko J, Polkowski WP, Skomra DG, Stanisławek AJ, Kurylcio AM, Korobowicz EM: Prognostic value of p27 kip1 expression in adenocarcinoma of the pancreatic head region. HPB (Oxford); 2006;8(3):216-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of p27 kip1 expression in adenocarcinoma of the pancreatic head region.
  • BACKGROUND: p27(kip1) is a tumour suppressor gene, functioning as a cyclin-dependent kinase inhibitor, and an independent prognostic factor in breast, colon, and prostate adenocarcinomas.
  • Conflicting data are reported for adenocarcinoma of the pancreas.
  • The aim of this study was to establish the prognostic value of p27(kip1) expression in adenocarcinoma of the pancreatic head region.
  • There were no significant correlations between p27(kip1) index and stage or lymph node involvement.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2004 May;91(5):586-94 [15122610.001]
  • [Cites] Pancreas. 2004 Apr;28(3):231-4 [15084962.001]
  • [Cites] Ann Surg Oncol. 2004 Nov;11(11):955-61 [15525823.001]
  • [Cites] Br J Surg. 1995 Jan;82(1):111-5 [7881926.001]
  • [Cites] Mol Cell. 1998 Mar;1(4):553-63 [9660939.001]
  • [Cites] Ann Surg. 1996 Feb;223(2):147-53 [8597508.001]
  • [Cites] Anticancer Res. 1995 Sep-Oct;15(5B):2181-6 [8572621.001]
  • [Cites] Pancreas. 1999 Jan;18(1):104-10 [9888666.001]
  • [Cites] Cancer. 1996 Feb 1;77(3):459-66 [8630952.001]
  • [Cites] Anticancer Res. 1995 Nov-Dec;15(6B):2659-68 [8669843.001]
  • [Cites] Nat Med. 1996 Nov;2(11):1204-10 [8898746.001]
  • [Cites] Int J Pancreatol. 1996 Dec;20(3):155-61 [9013275.001]
  • [Cites] J Immunother. 1997 Jan;20(1):70-8 [9101416.001]
  • [Cites] Hepatogastroenterology. 1997 Sep-Oct;44(17):1463-8 [9356873.001]
  • [Cites] Cancer Res. 1997 Dec 15;57(24):5441-5 [9407946.001]
  • [Cites] Ann Surg. 1998 Jun;227(6):821-31 [9637545.001]
  • [Cites] Am J Pathol. 1999 Feb;154(2):313-23 [10027389.001]
  • [Cites] Cancer. 1999 Mar 15;85(6):1250-60 [10189129.001]
  • [Cites] Eur J Surg. 1999 Apr;165(4):292-306 [10365829.001]
  • [Cites] Br J Cancer. 1999 Aug;80(11):1830-7 [10468306.001]
  • [Cites] Gastroenterology. 1999 Dec;117(6):1464-84 [10579989.001]
  • [Cites] Am Surg. 1999 Dec;65(12):1143-9 [10597062.001]
  • [Cites] Oncology. 2000;58(1):45-51 [10644940.001]
  • [Cites] J Cell Physiol. 2000 Apr;183(1):10-7 [10699961.001]
  • [Cites] J Pathol. 2000 Jun;191(2):154-61 [10861575.001]
  • [Cites] J Surg Oncol. 2000 May;74(1):36-40 [10861607.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2726-34 [10914717.001]
  • [Cites] Pancreas. 2000 Oct;21(3):226-30 [11039465.001]
  • [Cites] Int J Cancer. 2000 Nov 20;89(6):469-74 [11102889.001]
  • [Cites] Int J Oncol. 2001 Oct;19(4):709-15 [11562745.001]
  • [Cites] Lancet. 2001 Nov 10;358(9293):1576-85 [11716884.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2002;9(1):1-11 [12021893.001]
  • [Cites] Clin Cancer Res. 2002 Jun;8(6):1808-15 [12060621.001]
  • [Cites] Cancer. 2003 Apr 1;97(7):1591-600 [12655514.001]
  • [Cites] Hum Pathol. 2003 Apr;34(4):385-90 [12733121.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2003 Feb;2(1):142-6 [14607668.001]
  • [Cites] Am J Clin Pathol. 2003 Nov;120(5):685-90 [14608893.001]
  • [Cites] Oncology. 2003;65(4):371-7 [14707458.001]
  • [Cites] Oncol Rep. 2004 Feb;11(2):277-84 [14719054.001]
  • [Cites] Korean J Intern Med. 2004 Mar;19(1):10-4 [15053037.001]
  • [Cites] Pathol Int. 2004 Sep;54(9):675-81 [15363035.001]
  • (PMID = 18333280.001).
  • [ISSN] 1365-182X
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2131676
  •  go-up   go-down


69. Zhang J, Ding Y, Zhou Z, Li H, Zhou B: [Expression of human papillomavirus 16 E7 DNA in patients with colorectal adenocarcinoma]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2005 Oct;22(5):1024-6, 1044
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of human papillomavirus 16 E7 DNA in patients with colorectal adenocarcinoma].
  • The relationship between Human papillomavirus (HPV) 16 infection and the natural course of colorectal adenocarcinoma has not been fully defined.
  • In this study, the HPV 16 E7 DNA was detected in 82 patients with primary colorectal adenocarcinoma to study the relationship between HPV 16 infection and colorectal carcinoma.
  • The correlation was found between HPV16 E7 expression and tumor's location; the positive rate was 18.18% in the ascending colon carcinoma group and 64.10% in the rectal carcinoma group.
  • High HPV16 E7 expression was also associated with lower Dukes stage (P < 0.01).
  • These results indicated that there was correlation between colorectal adenocarcinoma and HPV 16 infection.
  • Specimens expressing higher levels of HPV 16 E7 DNA were associated with lower Dukes stage and more distal location.
  • [MeSH-major] Adenocarcinoma / virology. Colorectal Neoplasms / virology. Oncogene Proteins, Viral / biosynthesis. Papillomavirus Infections / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16294745.001).
  • [ISSN] 1001-5515
  • [Journal-full-title] Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi
  • [ISO-abbreviation] Sheng Wu Yi Xue Gong Cheng Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Oncogene Proteins, Viral; 0 / Papillomavirus E7 Proteins; 0 / oncogene protein E7, Human papillomavirus type 16
  •  go-up   go-down


70. Paik SS, Jang KS, Song YS, Jang SH, Min KW, Han HX, Na W, Lee KH, Choi D, Jang SJ: Reduced expression of Apaf-1 in colorectal adenocarcinoma correlates with tumor progression and aggressive phenotype. Ann Surg Oncol; 2007 Dec;14(12):3453-9
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced expression of Apaf-1 in colorectal adenocarcinoma correlates with tumor progression and aggressive phenotype.
  • We investigated the expression of Apaf-1 in colorectal tissues corresponding to the multistep carcinogenesis model to determine correlations between the clinicopathologic characteristics and the expression of this molecule and to evaluate the role of Apaf-1 in the development and progression of colorectal adenocarcinoma.
  • In the analyses between Apaf-1 expression and clinicopathologic parameters, reduced expression of Apaf-1 correlated with left colon location (p < 0.001), deeper tumor invasion (p < 0.001), frequent lymph node metastasis (p = 0.021), higher American Joint Committee on Cancer (AJCC) and Dukes' stage (p = 0.02 and p = 0.001, respectively) and poorer differentiation (p < 0.001).
  • The patient survival was significantly associated with age, histological grade, AJCC stage, and lymphovascular invasion, but not Apaf-1 expression (p = 0.478).
  • CONCLUSIONS: The results suggest that the loss of Apaf-1 expression is a relatively frequent late event and the loss of Apaf-1 expression may play an important role in tumorigenesis and tumor progression in colorectal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Apoptotic Protease-Activating Factor 1 / metabolism. Biomarkers, Tumor / metabolism. Colorectal Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17882496.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / APAF1 protein, human; 0 / Apoptotic Protease-Activating Factor 1; 0 / Biomarkers, Tumor
  •  go-up   go-down


71. Chen JM, Li WH, Wang JD, Feng YD, Wu JH, Gong JP: [Cell balance between apoptosis and proliferation in colon cancer and its correlation with prognosis]. Ai Zheng; 2005 May;24(5):554-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cell balance between apoptosis and proliferation in colon cancer and its correlation with prognosis].
  • This study was to investigate cell balance (ratio of apoptosis index to proliferation index, AI/PI) in colon cancer and its correlation with prognosis.
  • METHODS: The apoptotic population and the proliferating population of colon cancer cells were quantitatively analyzed by Sub-G1 method and Ki-67/DNA bivariate analysis of flow cytometry.
  • RESULTS: AI/PI ratio of cells was significantly higher in normal colon tissue than in colon adenoma tissue, Dukes' A colon cancer, Dukes' B colon cancer, and Dukes' C and D colon cancer (0.45+/-0.19 vs. 0.30+/-0.07, 0.29+/-0.11, 0.28+/-0.10, and 0.26+/-0.07, respectively, P < 0.01).
  • AI/PI ratio showed a down-regulating trend in variables tested including tumor size, pathologic type, differentiation grade, Dukes' stage, and nodal involvement.
  • AI/PI ratio of peripheral lymphocytes was significantly higher in colon cancer patients than in healthy people (0.64+/-0.11 vs. 0.49+/-0.12, P < 0.01).
  • The expression of Ki-67 was observed in normal colon tissue, colon adenoma, and colon cancer under confocal microscope.
  • CONCLUSIONS: Dysregulation (down-regulation or up-regulation) of cell balance between apoptosis and proliferation in colon cancer cells and lymphocytes might play an important role in tumorigenesis and tumor progression.
  • AI/PI ratio can' t be used as a prognostic factor of colon cancer.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenoma / metabolism. Adenoma / pathology. Adult. Aged. Cell Proliferation. Female. Follow-Up Studies. Homeostasis. Humans. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Staging. Prognosis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15890096.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


72. Kang H, O'Connell JB, Leonardi MJ, Maggard MA, McGory ML, Ko CY: Rare tumors of the colon and rectum: a national review. Int J Colorectal Dis; 2007 Feb;22(2):183-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare tumors of the colon and rectum: a national review.
  • This population-based evaluation is the first comprehensive look at four rare histologic types of CRC, allowing comparisons with the more common adenocarcinoma for clinical and pathological features and survival rates.
  • MATERIALS AND METHODS: All patients diagnosed with carcinoid (n=2,565), malignant lymphoma (n=955), non-carcinoid neuroendocrine (n=455), squamous cell (n=437), and adenocarcinoma (n=164,638) in SEER cancer database (1991-2000) were analyzed.
  • Evaluation of age-adjusted incidence rate, stage at presentation, and 5-year relative survival were determined for each histologic subtype.
  • Incidence rates in 2000 per million were: carcinoid 10.6, lymphoma 3.5, neuroendocrine 2.0, squamous 1.9, and adenocarcinoma 496.3.
  • Squamous (93.4%) and carcinoid (73.7%) tumors occurred more often in the rectum; lymphoma (79.0%), neuroendocrine (70.8%), and adenocarcinoma (70.1%) occurred more often in the colon (P<0.01).
  • Carcinoids presented at earlier stage (localized/regional, 90.5%) more often than adenocarcinoma (80.6%; p<0.01), but squamous cell (82.1%; p=0.50), lymphoma(70.6%; p<0.01), and neuroendocrine (37.8%; p<0.01) presented at earlier stage similarly or less often than adenocarcinoma.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Carcinoid Tumor / epidemiology. Carcinoid Tumor / pathology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Female. Humans. Lymphoma / epidemiology. Lymphoma / pathology. Male. Middle Aged. Neuroendocrine Tumors / epidemiology. Neuroendocrine Tumors / pathology. Survival Analysis. United States / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16845516.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


73. Fulmes M, Setrakian S, Raj PK, Bogard BM: Cancer biology and necrotic changes in metastatic lymph nodes and survival of colon cancer patients. Am J Surg; 2005 Mar;189(3):364-8
Genetic Alliance. consumer health - Metastatic cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer biology and necrotic changes in metastatic lymph nodes and survival of colon cancer patients.
  • BACKGROUND: Identifying factors that can contribute to a better understanding of tumor progression in stage III colon cancer patients continues to be an important task.
  • METHODS: The study included 48 consecutive colon and rectosigmoid cancer patients with stage III disease who underwent radical surgery.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Colonic Neoplasms / mortality. Colonic Neoplasms / pathology. Lymph Nodes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15792771.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Vaccaro CA, Im V, Rossi GL, Quintana GO, Benati ML, Perez de Arenaza D, Bonadeo FA: Lymph node ratio as prognosis factor for colon cancer treated by colorectal surgeons. Dis Colon Rectum; 2009 Jul;52(7):1244-50
Genetic Alliance. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymph node ratio as prognosis factor for colon cancer treated by colorectal surgeons.
  • PURPOSE: This study was designed to assess the prognostic value of the lymph node ratio in patients with colon cancer treated by colorectal specialists.
  • METHODS: Three hundred and sixty-two Stage III consecutive cases were analyzed based on quartiles: lymph node ratio 1 (>0 and <0.06); lymph node ratio 2 (between 0.06 and 0.12); lymph node ratio 3 (>0.12 and <0.25); lymph node ratio 4 (>or=0.25).
  • CONCLUSION: A lymph node ratio >or=0.25 was an independent prognostic factor in Stage III colon adenocarcinoma regardless of the number positive nodes.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Colonic Neoplasms / mortality. Colonic Neoplasms / pathology. Lymph Node Excision. Lymph Nodes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19571700.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Guo Q, Tang W, Inagaki Y, Midorikawa Y, Kokudo N, Sugawara Y, Nakata M, Konishi T, Nagawa H, Makuuchi M: Clinical significance of subcellular localization of KL-6 mucin in primary colorectal adenocarcinoma and metastatic tissues. World J Gastroenterol; 2006 Jan 7;12(1):54-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of subcellular localization of KL-6 mucin in primary colorectal adenocarcinoma and metastatic tissues.
  • Statistical analysis between clinicopathological factors and subcellular localization of KL-6 mucin showed that KL-6 localization in the circumferential membrane and/or cytoplasm was significantly associated with the presence of venous invasion (P = 0.0003), lymphatic invasion (P<0.0001), lymph node metastasis (P<0.0001), liver metastasis (P = 0.058), and advanced histological stage (P<0.0001).
  • CONCLUSION: The subcellular staining pattern of KL-6 in colorectal adenocarcinoma may be an important indicator for unfavorable behaviors such as lymph node and liver metastasis, as well as for the prognosis of patients.
  • [MeSH-major] Adenocarcinoma / chemistry. Antigens / analysis. Colorectal Neoplasms / chemistry. Glycoproteins / analysis. Mucins / analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1988 Mar 25;263(9):4215-22 [3346246.001]
  • [Cites] World J Gastroenterol. 2005 Sep 21;11(35):5450-4 [16222735.001]
  • [Cites] J Biol Chem. 1990 Sep 5;265(25):15286-93 [1697589.001]
  • [Cites] Int J Oncol. 2000 Mar;16(3):455-9 [10675475.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2000 Mar;278(3):L625-9 [10710536.001]
  • [Cites] Cancer. 2001 Jun 1;91(11):1973-82 [11391575.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):466-71 [11914624.001]
  • [Cites] World J Gastroenterol. 2001 Jun;7(3):425-30 [11819805.001]
  • [Cites] Biochem Biophys Res Commun. 2002 May 17;293(4):1183-90 [12054500.001]
  • [Cites] Histopathology. 2003 Mar;42(3):239-45 [12605643.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):5011-20 [12941828.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):45-60 [14681689.001]
  • [Cites] World J Gastroenterol. 2004 Oct 15;10(20):3044-7 [15378790.001]
  • [Cites] Hybridoma. 1984 Fall;3(3):223-32 [6094338.001]
  • [Cites] J Biol Chem. 1990 Sep 5;265(25):15294-9 [2394722.001]
  • [Cites] J Clin Oncol. 1991 Jul;9(7):1113-23 [2045853.001]
  • [Cites] Cancer Res. 1992 Apr 15;52(8):2318-24 [1559234.001]
  • [Cites] Cancer Res. 1992 May 1;52(9):2563-8 [1373671.001]
  • [Cites] Cancer. 1993 Apr 1;71(7):2191-9 [8384065.001]
  • [Cites] Gastroenterology. 1994 Feb;106(2):353-61 [7905449.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Feb;78(2):337-42 [8106621.001]
  • [Cites] J Cell Biol. 1995 Apr;129(1):255-65 [7698991.001]
  • [Cites] Annu Rev Physiol. 1995;57:607-34 [7778880.001]
  • [Cites] J Surg Oncol. 1996 Jul;62(3):171-6 [8667623.001]
  • [Cites] Nat Med. 1998 Jan;4(1):43-9 [9427605.001]
  • [Cites] Oncology. 1998 Jul-Aug;55(4):307-19 [9663420.001]
  • [Cites] Dis Colon Rectum. 1998 Oct;41(10):1262-72 [9788390.001]
  • [Cites] Hepatogastroenterology. 2005 Jan-Feb;52(61):67-71 [15782996.001]
  • [Cites] Jpn J Clin Oncol. 1988 Sep;18(3):203-16 [3411786.001]
  • (PMID = 16440417.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens; 0 / Antigens, Neoplasm; 0 / Glycoproteins; 0 / MUC1 protein, human; 0 / Mucin-1; 0 / Mucins
  • [Other-IDs] NLM/ PMC4077483
  •  go-up   go-down


76. Nakao K, Tsunoda A, Amagasa H, Suzuki N, Yamazaki K, Kusano M: [A case report of poorly-differentiated adenocarcinoma in sigmoid colon cancer with liver and pulmonary metastasis responding to TS-1 and CPT-11]. Gan To Kagaku Ryoho; 2006 Jan;33(1):109-12
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of poorly-differentiated adenocarcinoma in sigmoid colon cancer with liver and pulmonary metastasis responding to TS-1 and CPT-11].
  • Pathological findings were type 3, 30 x 20 mm, poorly-differentiated adenocarcinoma, se, ly 2, v 2, n 2 (+), ow (-), aw(-), H 3, P 0 (stage IV).
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Sigmoid Neoplasms / drug therapy. Sigmoid Neoplasms / pathology

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16410709.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


77. Viehl CT, Ochsner A, von Holzen U, Cecini R, Langer I, Guller U, Laffer U, Oertli D, Zuber M: Inadequate quality of surveillance after curative surgery for colon cancer. Ann Surg Oncol; 2010 Oct;17(10):2663-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inadequate quality of surveillance after curative surgery for colon cancer.
  • BACKGROUND: Colon cancer patients are at risk for recurrence.
  • The objective of this study is to analyze the quality of surveillance after curative surgery for colon cancer among a cohort of Swiss patients.
  • PATIENTS AND METHODS: After curative surgery, 129 stage I-III colon cancer patients were followed by chart review, questionnaires, and phone interviews.
  • CONCLUSIONS: The quality of surveillance after curative surgery for colon cancer among a cohort of Swiss patients is inadequate.
  • [MeSH-major] Adenocarcinoma / surgery. Colonic Neoplasms / surgery. Continuity of Patient Care

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20429036.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


78. Sinicrope FA, Rego RL, Foster N, Sargent DJ, Windschitl HE, Burgart LJ, Witzig TE, Thibodeau SN: Microsatellite instability accounts for tumor site-related differences in clinicopathologic variables and prognosis in human colon cancers. Am J Gastroenterol; 2006 Dec;101(12):2818-25
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microsatellite instability accounts for tumor site-related differences in clinicopathologic variables and prognosis in human colon cancers.
  • OBJECTIVE: Colon cancers with high frequency microsatellite instability (MSI-H) are preferentially located in the proximal colon.
  • Given that 15-20% of sporadic colon cancers are MSI-H, we determined whether tumor site-specific differences in clinicopathological variables, biomarkers, and prognosis are due to inclusion of MSI-H cases.
  • METHODS: TNM stage II and III primary colon carcinomas (N = 528) from patients enrolled in 5-fluorouracil-based adjuvant trials were analyzed for MSI using 11 microsatellite markers.
  • RESULTS: MSI-H was found in 95 (18%) colon cancers.
  • CONCLUSIONS: Tumor site-related differences in clinicopathological variables, biomarkers, and prognosis of sporadic colon cancers can be explained by the inclusion of MSI-H cases.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17026563.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA074800; United States / NCI NIH HHS / CA / CA 104683
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / DNA-Binding Proteins; 0 / G-T mismatch-binding protein; 0 / MLH1 protein, human; 0 / Nuclear Proteins; 0 / Tumor Suppressor Protein p53; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
  •  go-up   go-down


79. Berger AC, Sigurdson ER, LeVoyer T, Hanlon A, Mayer RJ, Macdonald JS, Catalano PJ, Haller DG: Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol; 2005 Dec 1;23(34):8706-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes.
  • PATIENTS AND METHODS: We analyzed data from Intergroup trial 0089 of adjuvant chemotherapy for stage II and III patients with colon cancer, in which all patients received fluorouracil-based therapy.
  • Covariates included in the models were age, sex, tumor stage, grade, histology, number of positive LNs, number of LNs removed, and LNR.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / therapy. Lymphatic Metastasis / pathology

  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16314630.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Fazeli MS, Adel MG, Lebaschi AH: Colorectal carcinoma: a retrospective, descriptive study of age, gender, subsite, stage, and differentiation in Iran from 1995 to 2001 as observed in Tehran University. Dis Colon Rectum; 2007 Jul;50(7):990-5
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal carcinoma: a retrospective, descriptive study of age, gender, subsite, stage, and differentiation in Iran from 1995 to 2001 as observed in Tehran University.
  • These factors also are evaluated in conjunction with disease stage and tumor differentiation at the time of diagnosis.
  • METHODS: Data from 419 patients from a population that receives no screening between April 1995 and March 2001 operated on in the Cancer Institute and Imam Khomieni Hospital with a diagnosis of colorectal cancer were used to describe distribution of the colorectal carcinoma by age, gender, tumor subsite and pathology, and stage at diagnosis.
  • RESULTS: There were 403 (96.2 percent) cases of adenocarcinoma.
  • Patients were divided into two age groups (40 years and younger, and older than 40 years); 16.4 percent of patients had tumors in the proximal colon and 83.6 percent in distal parts.
  • Most patients were Stage II and III (48.1 and 33.4 percent, respectively).
  • Most patients in the younger age group were Stage III (45 percent) and in the older age group were Stage II (53.2 percent; P<0.001).
  • There were no differences in stage and tumor differentiation between two genders, but most of the patients with tumors in proximal colon were males (62.5 percent; P=0.1).
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Colorectal Neoplasms / epidemiology. Colorectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17525859.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Baton O, Lasser P, Sabourin JC, Boige V, Duvillard P, Elias D, Malka D, Ducreux M, Pocard M: Ex vivo sentinel lymph node study for rectal adenocarcinoma: preliminary study. World J Surg; 2005 Sep;29(9):1166-70, discussion 1171

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ex vivo sentinel lymph node study for rectal adenocarcinoma: preliminary study.
  • Intraoperative sentinel lymph node (SLN) detection has been reported for colon cancer, but no study has focused on rectal cancer.
  • We evaluated SLN detection using blue dye injection in patients with rectal adenocarcinoma.
  • A micrometastasis was discovered in 3 of 23 pNO cases when H&E was used on multisection levels, thus changing the stage to pN1.
  • However, SLNs detection can change the tumor stage by upstaging nearly 15% of the tumors from T2-3N0 to T2-3 N+.
  • [MeSH-major] Adenocarcinoma / pathology. Rectal Neoplasms / pathology. Sentinel Lymph Node Biopsy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16086211.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Yamamoto S, Kawahara K, Maekawa T, Shiraishi T, Shirakusa T: Minimally invasive esophagectomy for stage I and II esophageal cancer. Ann Thorac Surg; 2005 Dec;80(6):2070-5
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimally invasive esophagectomy for stage I and II esophageal cancer.
  • The histologic type of cancer was squamous cell carcinoma in 109 (97.4%) patients and adenocarcinoma in 3 (2.6%).
  • Induction chemoradiotherapy, preoperative concomitant disease, and reconstruction using the colon did not increase morbidity.
  • For stage I disease, the 5-year survival rate of patients was 87.2%.
  • In stage II disease, it was 70.2%.
  • The survival of patients with stage I and II disease is satisfactory at the present time.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / pathology. Esophageal Neoplasms / surgery. Esophagectomy / methods. Thoracic Surgery, Video-Assisted

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16305846.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


83. Becker L, Huang Q, Mashimo H: Lgr5, an intestinal stem cell marker, is abnormally expressed in Barrett's esophagus and esophageal adenocarcinoma. Dis Esophagus; 2010 Feb;23(2):168-74
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lgr5, an intestinal stem cell marker, is abnormally expressed in Barrett's esophagus and esophageal adenocarcinoma.
  • Lgr5 (leucine-rich-repeat-containing G-protein-coupled receptor 5), a recently discovered intestinal stem cell marker, is expressed in premalignant lesions including Barrett's esophagus (BE) and cancers including colon cancer, ovarian cancer, and hepatocellular carcinoma.
  • It was also recently found to be expressed in tumor spheres prepared from colon cancer, suggesting that it will likely serve as a cancer stem cell marker.
  • Using standard immunohistochemistry, we performed immunostaining on 81 esophageal specimens (53 biopsy specimens and 28 surgical resections) representing BE, BE-associated dysplasia, and esophageal adenocarcinoma (EAC).
  • In EAC, high Lgr5 expression scores (> or = 5) were associated with worse survival, independent of stage, age, and neoadjuvant/adjuvant therapy (P = 0.03).
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Esophageal Neoplasms / pathology. Receptors, G-Protein-Coupled / analysis

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19549212.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] eng
  • [Grant] United States / BLRD VA / BX / I01 BX000663; United States / NIDDK NIH HHS / DK / T32 DK 07760
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / Coloring Agents; 0 / LGR5 protein, human; 0 / Receptors, G-Protein-Coupled
  •  go-up   go-down


84. Xie L, Villeneuve PJ, Shaw A: Survival of patients diagnosed with either colorectal mucinous or non-mucinous adenocarcinoma: a population-based study in Canada. Int J Oncol; 2009 Apr;34(4):1109-15
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival of patients diagnosed with either colorectal mucinous or non-mucinous adenocarcinoma: a population-based study in Canada.
  • Previous studies have shown conflicting results on the prognosis of colorectal mucinous adenocarcinoma.
  • Analyses were based on 165 colorectal mucinous and 1215 non-mucinous adenocarcinoma patients who were registered at the Ottawa Regional Cancer Centre from 1994 to 1997, with follow-up extending to December 31, 2001.
  • For colon, rectum and both combined, the distribution for age at diagnosis, stage and treatment of patients with mucinous adenocarcinoma was similar to that of non-mucinous patients (all p > or = 0.12).
  • Overall, no statistically significant differences were noted in 5-year relative survival between mucinous and non-mucinous carcinoma for colon, rectum and their combination (p > or = 0.35 for each).
  • However, when the stages were considered separately, patients with stage III mucinous carcinoma had worse survival than patients with non-mucinous carcinoma for both sites.
  • Multivariate analysis of combined data for colon and rectal cancers indicated that independent significant prognostic factors were stage for mucinous, with age and grade as well as stage for non-mucinous carcinoma.
  • In conclusion, no significant differences in stage distribution and overall survival were found between mucinous and non-mucinous patients for colorectal cancer.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma, Mucinous / mortality. Colorectal Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19287969.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


85. Choi D, Lee HW, Hur KY, Kim JJ, Park GS, Jang SH, Song YS, Jang KS, Paik SS: Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J Gastroenterol; 2009 May 14;15(18):2258-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma.
  • AIM: To verify that CD markers are available for detecting cancer stem cell populations and to evaluate their clinical significance in colon cancer.
  • RESULTS: In colorectal adenocarcinoma, 128 of 523 cases (24.5%) were positive and 395 cases (75.5%) were negative for CD133 expression.
  • Upon clinicopathological analysis, CD133 expression was present more in male patients (P = 0.002) and in advanced T stage cancer (P = 0.024).
  • CONCLUSION: CD markers were related to invasiveness and differentiation of colorectal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma. Antigens, CD / metabolism. Antigens, CD24 / metabolism. Biomarkers, Tumor / metabolism. Colorectal Neoplasms. Glycoproteins / metabolism. Neoplasm Invasiveness. Neoplastic Stem Cells / metabolism. Peptides / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Cancer J. 2007 May-Jun;13(3):192-7 [17620769.001]
  • [Cites] J Immunol. 1986 May 15;136(10):3779-84 [2939133.001]
  • [Cites] J Immunol. 1990 Jan 15;144(2):638-41 [2153173.001]
  • [Cites] J Immunol. 1991 Aug 15;147(4):1412-6 [1831224.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19):5264-70 [1327504.001]
  • [Cites] Cancer Res. 1993 Oct 15;53(20):4754-6 [7691404.001]
  • [Cites] Nature. 1994 Feb 17;367(6464):645-8 [7509044.001]
  • [Cites] Virchows Arch. 1994;425(4):399-406 [7820302.001]
  • [Cites] Am J Pathol. 1996 Nov;149(5):1519-30 [8909242.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Carcinogenesis. 2005 Feb;26(2):495-502 [15513931.001]
  • [Cites] Cell. 2005 May 6;121(3):465-77 [15882627.001]
  • [Cites] Pathol Res Pract. 2005;201(7):479-86 [16164042.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6574-81 [16166435.001]
  • [Cites] Cell. 2006 Aug 25;126(4):663-76 [16904174.001]
  • [Cites] N Engl J Med. 2006 Sep 21;355(12):1253-61 [16990388.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):973-8 [17210912.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1030-7 [17283135.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3153-61 [17409422.001]
  • [Cites] Mod Pathol. 2003 Apr;16(4):376-88 [12692203.001]
  • (PMID = 19437567.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Antigens, CD24; 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Peptides
  • [Other-IDs] NLM/ PMC2682242
  •  go-up   go-down


86. Nawa T, Kato J, Kawamoto H, Okada H, Yamamoto H, Kohno H, Endo H, Shiratori Y: Differences between right- and left-sided colon cancer in patient characteristics, cancer morphology and histology. J Gastroenterol Hepatol; 2008 Mar;23(3):418-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences between right- and left-sided colon cancer in patient characteristics, cancer morphology and histology.
  • BACKGROUND AND AIM: Recently, the clinical and biological differences between right- and left-sided colon cancers have been widely debated.
  • METHODS: A total of 3552 consecutive Japanese colorectal cancer cases were examined and the clinical differences between right- and left-sided colon cancer cases were investigated.
  • RESULTS: The proportion of right-sided colon cancer was relatively high in patients aged less than 40 years (33%) and more than 80 years (43%).
  • The proportion of right-sided colon cancer in patients aged 40-59 years was relatively low (male 22% and female 29%).
  • Right-sided colon cancer was more likely to be detected at an advanced stage (T1 stage; left 22%, right 15%) (P < 0.01) with severe symptoms.
  • Polypoid-type early cancer was dominant in the left colon (left 59%; right 40%) (P < 0.01), while the proportion of flat-type early cancer in the right colon was significantly higher than that in the left colon (left 25%; right 44%) (P < 0.01).
  • CONCLUSIONS: Specific age distribution of right-sided colon cancer was observed and the difference between male and female patients was highlighted.
  • Other clinical features also differed between right- and left-sided colon cancer, suggesting that different mechanisms may be at work during right and left colon carcinogenesis.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / pathology. Carcinoma, Signet Ring Cell / pathology. Colonic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17532785.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Australia
  •  go-up   go-down


87. Kornmann M, Formentini A, Ette C, Henne-Bruns D, Kron M, Sander S, Baumann W, Kreuser ED, Staib L, Link KH: Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment. Eur J Surg Oncol; 2008 Dec;34(12):1316-21
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment.
  • AIM: Adjuvant chemotherapy is recommended for stage III colon cancer.
  • The aim of this study was to identify important prognostic factors among patients with colon cancer receiving adjuvant 5-FU-based treatment.
  • METHODS: Data sets of 855 colon cancer patients treated between 1992 and 1999 within a multicenter adjuvant trial comparing 5-FU modulation with folinic acid or interfereron-alpha were examined.
  • In the future, this may result in adjuvant treatment of stage III colon cancer adjusted for the risk of substages.
  • [MeSH-major] Adenocarcinoma / mortality. Antimetabolites, Antineoplastic / therapeutic use. Colonic Neoplasms / mortality. Fluorouracil / therapeutic use

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18313881.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Immunologic Factors; 0 / Interferon-alpha; 12001-76-2 / Vitamin B Complex; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


88. Luo R, Giordano SH, Zhang DD, Freeman J, Goodwin JS: The role of the surgeon in whether patients with lymph node-positive colon cancer see a medical oncologist. Cancer; 2007 Mar 1;109(5):975-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of the surgeon in whether patients with lymph node-positive colon cancer see a medical oncologist.
  • BACKGROUND: Chemotherapy improves survival for patients with stage III colon cancer, but some older patients with lymph node-positive colon cancer do not see a medical oncologist and, thus, do not receive adjuvant chemotherapy.
  • METHODS: To evaluate the role of the surgeon in determining referrals to medical oncology among patients with stage III colon cancer, the authors conducted a retrospective cohort study of 6158 patients aged >or=66 years who were diagnosed with stage III colon cancer from 1992 through 1999 by using the Surveillance, Epidemiology, and End Results-Medicare linked database.
  • The individual surgeon characteristics that significantly predicted whether the patient saw a medical oncologist were year since graduation (<or=10 years vs >20 years; hazard ratio [HR], 1.60; 95% confidence interval [95% CI], 1.19-2.16), practicing in a teaching hospital (yes vs. no: HR; 1.30; 95% CI, 1.07-1.58), and volume of patients with colon cancer (<30 patients vs >or=121 patients; HR, 0.66; 95% CI, 0.46-0.94).
  • Interventions at the level of the surgeon may be appropriate to improve the care of patients with colon cancer.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Epidemiol. 2000 Dec;53(12):1258-67 [11146273.001]
  • [Cites] Oncologist. 2006 Oct;11(9):1025-33 [17030645.001]
  • [Cites] Cancer J. 2001 May-Jun;7(3):213-8 [11419029.001]
  • [Cites] N Engl J Med. 2001 Oct 11;345(15):1091-7 [11596588.001]
  • [Cites] Ann Intern Med. 2002 Mar 5;136(5):349-57 [11874307.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1716-8 [11919225.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1786-92 [11919235.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-3-18 [12187163.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-82-95 [12187173.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-96-103 [12187174.001]
  • [Cites] Ann Surg Oncol. 2003 Jul;10(6):606-15 [12839844.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4627-35 [14673052.001]
  • [Cites] Med Care. 2004 Sep;42(9):901-6 [15319616.001]
  • [Cites] Med Care. 1985 Aug;23(8):939-45 [4021579.001]
  • [Cites] Med Care. 1991 Jan;29(1):50-63 [1986177.001]
  • [Cites] BMJ. 1991 May 25;302(6787):1250-2 [2043851.001]
  • [Cites] Cancer. 1993 Jul 15;72(2):594-601 [8319193.001]
  • [Cites] Gastroenterology. 1994 Apr;106(4):899-906 [8143995.001]
  • [Cites] Br J Cancer. 1994 Aug;70(2):363-70 [8054286.001]
  • [Cites] N Engl J Med. 1994 Dec 15;331(24):1625-9 [7969344.001]
  • [Cites] Lancet. 1995 Apr 15;345(8955):939-44 [7715291.001]
  • [Cites] Med Care. 1996 May;34(5):479-89 [8614169.001]
  • [Cites] Health Serv Res. 1996 Apr;31(1):5-19 [8617610.001]
  • [Cites] Cancer. 1996 Aug 15;78(4):918-26 [8756390.001]
  • [Cites] J Fam Pract. 1997 Jul;45(1):47-53 [9228914.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):295-300 [9440756.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1349-55 [10334518.001]
  • [Cites] Lancet. 2005 Jan 8-14;365(9454):153-65 [15639298.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 17;97(16):1211-20 [16106026.001]
  • [Cites] JAMA. 2005 Dec 7;294(21):2703-11 [16333005.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):850-7 [11390534.001]
  • (PMID = 17265530.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA105631; United States / NCI NIH HHS / CA / R01 CA104949; United States / AHRQ HHS / HS / R24 HS011618
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS19823; NLM/ PMC1851914
  •  go-up   go-down


89. Chang GJ, Hu CY, Eng C, Skibber JM, Rodriguez-Bigas MA: Practical application of a calculator for conditional survival in colon cancer. J Clin Oncol; 2009 Dec 10;27(35):5938-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Practical application of a calculator for conditional survival in colon cancer.
  • In this study we performed a contemporary evaluation of conditional survival among colon cancer patients and created a browser-based tool for real-time determination of conditional survival expectancies.
  • PATIENTS AND METHODS: Patients with colon adenocarcinoma diagnosed between 1988 and 2000 were identified from the Surveillance Epidemiology End Results (SEER) registry.
  • Conditional survival estimates were calculated by using the multiplicative law of probability after adjustment for age; sex; ethnicity; grade; and American Joint Commission on Cancer, sixth edition stage.
  • As the time alive after initial treatment increased from 0 to 5 years, significant improvements in CS were observed for patients in all stages except stage I, which was associated with good CS even at diagnosis and which reflected the high likelihood of cure.
  • Notably, adjusted 5-year CS rates improved from 42% to 80% for stage IIIC cancers and from 5% to 48% for stage IV cancers during the first 5 years.
  • CONCLUSION: For patients with colon cancer who survive over time, 5-year, cancer-specific CS improved dramatically, and the greatest improvements were among patients with poorer initial prognoses.
  • [MeSH-major] Adenocarcinoma / mortality. Colonic Neoplasms / mortality. Health Status Indicators

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19805670.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


90. Vandoros GP, Konstantinopoulos PA, Sotiropoulou-Bonikou G, Kominea A, Papachristou GI, Karamouzis MV, Gkermpesi M, Varakis I, Papavassiliou AG: PPAR-gamma is expressed and NF-kB pathway is activated and correlates positively with COX-2 expression in stromal myofibroblasts surrounding colon adenocarcinomas. J Cancer Res Clin Oncol; 2006 Feb;132(2):76-84

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PPAR-gamma is expressed and NF-kB pathway is activated and correlates positively with COX-2 expression in stromal myofibroblasts surrounding colon adenocarcinomas.
  • The present study investigated the role of PPARgamma, COX-2 and p-IkB-alpha--important molecular targets of colon cancer chemoprevention--in this stromal remodeling by evaluating and comparing the expression of these factors in stromal myofibroblasts, macrophages and endothelial cells that surround normal colonic mucosa and colon cancer.
  • METHODS: Immunohistochemical methodology was employed on archived paraffin-embedded sections prepared from tumors and adjacent normal colon from 45 patients with colon adenocarcinomas.
  • RESULTS: Stromal macrophages and endothelial cells expressed these factors both in normal colonic mucosa and colon cancer.
  • By contrast, stromal myofibroblasts expressed PPARgamma, COX-2 and p-IkB-alpha only in colon adenocarcinomas (77.7%, 100% and 100% of cases, respectively) and not in normal colon.
  • PPARgamma, COX-2 and p-IkB-alpha expression did not correlate with the stage or differentiation of the adenocarcinomas.
  • CONCLUSIONS: NF-kB pathway is activated and COX-2 expression is upregulated in stromal myofibroblasts surrounding colon adenocarcinomas compared to normal colon.
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor / analysis. Colonic Neoplasms / chemistry. Cyclooxygenase 2 / analysis. Membrane Proteins / analysis. NF-kappa B / metabolism. PPAR gamma / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16215757.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Proteins; 0 / NF-kappa B; 0 / PPAR gamma; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


91. Rego RL, Foster NR, Smyrk TC, Le M, O'Connell MJ, Sargent DJ, Windschitl H, Sinicrope FA: Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. Br J Cancer; 2010 Jan 5;102(1):165-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status.
  • BACKGROUND: Evidence suggests that epidermal growth factor receptor (EGFR)-activation status may better predict the clinical behaviour of colon cancers than does EGFR expression.
  • However, the prognostic effect of phospho-EGFR in primary colon cancer remains undefined.
  • METHODS: Phospho-EGFR (Tyr-1173) and EGFR expression were analysed by immunohistochemistry (IHC) in tissue microarrays of TNM stage II and III colon cancers from completed adjuvant therapy trials (n=388).
  • Although phospho-EGFR was unrelated to clinicopathological variables, strong EGFR intensity was associated with higher tumour stage (P=0.03).
  • Stage and lymph node number were prognostic for DFS and OS, and histological grade for OS.
  • EGFR was an independent predictor of DFS (P=0.042) after adjustment for stage, histological grade, age, and MMR status.

  • COS Scholar Universe. author profiles.
  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1572-82 [15117979.001]
  • [Cites] Mol Cell Biol. 2003 Nov;23(21):7875-86 [14560030.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6487-501 [15475436.001]
  • [Cites] Science. 1993 May 7;260(5109):816-9 [8484122.001]
  • [Cites] Cancer Res. 1993 Dec 15;53(24):5849-52 [8261392.001]
  • [Cites] J Biol Chem. 1994 Jul 15;269(28):18674-8 [8034616.001]
  • [Cites] Eur J Surg Oncol. 1995 Jun;21(3):269-75 [7781795.001]
  • [Cites] Biochemistry. 1995 Dec 19;34(50):16456-66 [8845374.001]
  • [Cites] Gastroenterology. 1996 Mar;110(3):669-74 [8608874.001]
  • [Cites] Cancer Res. 1998 Apr 15;58(8):1713-8 [9563488.001]
  • [Cites] Clin Cancer Res. 1995 Jan;1(1):19-31 [9815883.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 4;91(15):1295-303 [10433618.001]
  • [Cites] J Biol Chem. 1999 Sep 10;274(37):26091-7 [10473558.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):102-8 [15598946.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1803-10 [15677699.001]
  • [Cites] Int J Oncol. 2005 Aug;27(2):317-25 [16010411.001]
  • [Cites] Mod Pathol. 2005 Oct;18(10):1350-6 [15832190.001]
  • [Cites] Semin Oncol. 2005 Dec;32(6 Suppl 9):S59-62 [16399434.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1169-77 [16505437.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2834-43 [16510606.001]
  • [Cites] Clin Cancer Res. 2006 May 1;12(9):2738-44 [16675565.001]
  • [Cites] Clin Colorectal Cancer. 2006 Jul;6(2):133-9 [16945169.001]
  • [Cites] Gastroenterology. 2006 Sep;131(3):729-37 [16952542.001]
  • [Cites] Br J Cancer. 2006 Dec 4;95(11):1525-8 [17088913.001]
  • [Cites] Int J Cancer. 2007 Mar 15;120(6):1232-8 [17187355.001]
  • [Cites] Lung Cancer. 2007 Mar;55(3):349-55 [17161498.001]
  • [Cites] J Clin Oncol. 2007 May 1;25(13):1658-64 [17470858.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2184-90 [17538163.001]
  • [Cites] Clin Cancer Res. 2007 Jun 15;13(12):3597-604 [17575224.001]
  • [Cites] J Clin Oncol. 2007 Oct 1;25(28):4405-13 [17906204.001]
  • [Cites] Ann Oncol. 2008 Dec;19(12):2033-8 [18632722.001]
  • [Cites] Pathology. 2009;41(4):356-60 [19404848.001]
  • [Cites] Curr Opin Oncol. 2009 Jul;21(4):369-73 [19444104.001]
  • [Cites] Clin Cancer Res. 2009 Jul 15;15(14):4531-7 [19584170.001]
  • [Cites] N Engl J Med. 2000 Jan 13;342(2):69-77 [10631274.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1739-57 [10738234.001]
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2225-31 [10786688.001]
  • [Cites] Int J Cancer. 2000 Oct 1;88(1):77-81 [10964085.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1521-6 [11818567.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1735-43 [11919229.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):945-54 [11948098.001]
  • [Cites] Eur J Cancer. 2002 May;38(8):1065-71 [12008194.001]
  • [Cites] Eur J Cancer. 2002 Nov;38(17):2258-64 [12441262.001]
  • [Cites] Eur J Cancer. 2003 Jul;39(10):1348-54 [12826036.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):247-57 [12867608.001]
  • [Cites] Virchows Arch. 2003 Aug;443(2):115-21 [12802583.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3069-75 [15131045.001]
  • (PMID = 19997103.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK084567; United States / NCI NIH HHS / CA / R01 CA104683; United States / NCI NIH HHS / CA / CA 104683
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 21820-51-9 / Phosphotyrosine; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2813748
  •  go-up   go-down


92. Billingsley KG, Morris AM, Dominitz JA, Matthews B, Dobie S, Barlow W, Wright GE, Baldwin LM: Surgeon and hospital characteristics as predictors of major adverse outcomes following colon cancer surgery: understanding the volume-outcome relationship. Arch Surg; 2007 Jan;142(1):23-31; discussion 32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgeon and hospital characteristics as predictors of major adverse outcomes following colon cancer surgery: understanding the volume-outcome relationship.
  • PATIENTS: Patients aged 66 years and older, diagnosed and surgically treated for stage I, II, or III colon cancer between 1992 and 1996 (n = 22 672).
  • [MeSH-major] Adenocarcinoma / surgery. Colonic Neoplasms / surgery. Digestive System Surgical Procedures / utilization. Hospitals / utilization. Outcome Assessment (Health Care)

  • MedlinePlus Health Information. consumer health - Health Facilities.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17224497.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Zheng LD, Tong QS, Weng MX, He J, Lv Q, Pu JR, Jiang GS, Cai JB, Liu Y, Hou XH: Enhanced expression of resistin-like molecule beta in human colon cancer and its clinical significance. Dig Dis Sci; 2009 Feb;54(2):274-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced expression of resistin-like molecule beta in human colon cancer and its clinical significance.
  • Previous studies have indicated that resistin-like molecule beta (RELM beta), an intestinal goblet cell-specific protein, is markedly increased in the intestinal tumors of min mice and over-expressed in a human colon cancer cell line.
  • We hypothesized that RELM beta might be enhanced in human colon cancer.
  • The aim of this study was to examine the clinical importance of RELM beta expression in colon cancer patients and to correlate its expression with various clinicopathological parameters, upstream regulatory molecule expression, tumor proliferative capacity, and patients' survival.
  • Of the 80 colon cancer patients studied, 65 (81.25%) tested positive for RELM beta, mainly in the cytoplasm of colon mucosa.
  • Contrasting sharply with the strongly RELM beta-positive tumors, normal colon mucous membrane was negative or weakly positive.
  • RELM beta positivity in colon cancer was correlated with histological grade of differentiation and lymph node metastasis, but not with age, gender, tumor location and size, tumor infiltration, Dukes' stage, liver metastasis, and venous invasion.
  • These findings support evidence of the enhanced RELM beta expression in colon cancer patients and suggest that further investigation is warranted to explore the role of RELM beta in colon cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Colonic Neoplasms / metabolism. Goblet Cells / metabolism. Intercellular Signaling Peptides and Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. China / epidemiology. Colon / pathology. Female. Gene Expression Regulation, Neoplastic. Homeodomain Proteins / metabolism. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18594973.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Ki-67 Antigen; 0 / RETNLB protein, human
  •  go-up   go-down


94. Kim ST, Lee J, Park SH, Park JO, Lim HY, Kang WK, Kim JY, Kim YH, Chang DK, Rhee PL, Kim DS, Yun H, Cho YB, Kim HC, Yun SH, Lee WY, Chun HK, Park YS: Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemother Pharmacol; 2010 Sep;66(4):659-67
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
  • PURPOSE: Colon cancer with DNA mismatch repair (MMR) defects reveals indistinguishable clinical and pathologic aspects, including better prognosis and reduced response to 5-fluorouracil (5-FU)-based chemotherapy.
  • This study investigated the clinical implication of MSI-H/MMR-D and p53 expression in R0-resected colon cancer patients who received adjuvant oxaliplatin/5-FU/leucovorin (FOLFOX) therapy.
  • EXPERIMENTAL DESIGN: We analyzed 135 patients, who had been treated by adjuvant chemotherapy containing 5-FU and oxaliplatin (FOLFOX) after curative resection (R0) for colon adenocarcinoma between May 2004 and November 2007.
  • RESULTS: There were 13 (9.6%) patients with stage II, 108 (80%) with stage III, and 14 (10.4%) with stage IV.
  • Fourteen patients with stage IV (10.3%) had metastases to liver only, all of whom underwent complete metastasectomy for liver metastases.
  • MMR status was not significantly associated with DFS (P = 0.56) or OS (P = 0.61) in patients with colon cancer (n = 135) receiving adjuvant FOLFOX.
  • CONCLUSION: The MMR status or p53 positivity was not significantly associated with outcomes to FOLFOX as adjuvant chemotherapy in colon cancer patients with R0 resection.
  • Adding oxaliplatin in adjuvant chemotherapy may overcome negative impact of 5-FU on colon cancers with MSI-H/MMR-D.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Colonic Neoplasms / genetics. Microsatellite Instability / drug effects

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20033812.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Genetic Markers; 0 / Organoplatinum Compounds; 0 / Tumor Suppressor Protein p53; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


95. Clark-Langone KM, Sangli C, Krishnakumar J, Watson D: Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX Colon Cancer Assay. BMC Cancer; 2010;10:691
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX Colon Cancer Assay.
  • BACKGROUND: The Oncotype DX Colon Cancer Assay is a new diagnostic test for determining the likelihood of recurrence in stage II colon cancer patients after surgical resection using fixed paraffin embedded (FPE) primary colon tumor tissue.
  • By capturing the biology underlying each patient's tumor, the Oncotype DX Colon Cancer Assay provides a Recurrence Score (RS) that reflects an individualized risk of disease recurrence.
  • CONCLUSIONS: Analytical performance characteristics shown here for both individual genes and gene groups in the Oncotype DX Colon Cancer Assay demonstrate consistent translation of specific biology of individual tumors into clinically useful diagnostic information.
  • The results of these studies illustrate how the analytical capability of the Oncotype DX Colon Cancer Assay has enabled clinical validation of a test to determine individualized recurrence risk after colon cancer surgery.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma, Mucinous / genetics. Biomarkers, Tumor / genetics. Colonic Neoplasms / genetics. Genetic Testing / methods. Molecular Diagnostic Techniques. Neoplasm Recurrence, Local / genetics. Precision Medicine. Reverse Transcriptase Polymerase Chain Reaction


96. Liang JT, Lai HS, Lee PH, Chang KJ: Laparoscopic pelvic autonomic nerve-preserving surgery for sigmoid colon cancer. Ann Surg Oncol; 2008 Jun;15(6):1609-16

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic pelvic autonomic nerve-preserving surgery for sigmoid colon cancer.
  • BACKGROUND: To test the feasibility of laparoscopic approach in performing the simultaneous pelvic autonomic nerve preservation during standard anterior resection of sigmoid colon cancer.
  • RESULTS: A total of 112 patients (tumor, node, metastasis system stage I, n = 8; stage II, n = 54; stage III, n = 50; male, n = 58; female, n = 54; age [mean +/- standard deviation], 55.8 +/- 6.4 years) with good baseline genitourinary function were operated on with the intent of total preservation of pelvic autonomic nerves and curative resection of sigmoid colon cancer.
  • CONCLUSIONS: Under laparoscopy, we can clearly identify and preserve the pelvic autonomic nerves to retain genitourinary function in most patients undergoing oncologic resection of sigmoid colon cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Autonomic Pathways / surgery. Colectomy. Sigmoid Neoplasms / surgery. Trauma, Nervous System / prevention & control

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2004 Apr;91(4):465-8 [15048749.001]
  • [Cites] Tech Coloproctol. 2003 Apr;7(1):29-33 [12750952.001]
  • [Cites] Dis Colon Rectum. 2005 Dec;48(12):2354-61 [16408331.001]
  • [Cites] Br J Surg. 2005 Nov;92(11):1444-8 [16184622.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1124-32 [15997446.001]
  • [Cites] Ann Surg. 2005 Aug;242(2):212-23 [16041212.001]
  • [Cites] World J Surg. 2003 Feb;27(2):190-6 [12616435.001]
  • [Cites] Dis Colon Rectum. 2002 Sep;45(9):1178-85 [12352233.001]
  • [Cites] J Sex Marital Ther. 2000 Apr-Jun;26(2):191-208 [10782451.001]
  • [Cites] Semin Surg Oncol. 2000 Apr-May;18(3):235-43 [10757889.001]
  • [Cites] Hepatogastroenterology. 2004 Sep-Oct;51(59):1354-7 [15362751.001]
  • [Cites] Hepatogastroenterology. 1998 Nov-Dec;45(24):2206-14 [9951896.001]
  • [Cites] Ann Surg Oncol. 2007 Apr;14(4):1285-7 [17235719.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):109-17 [17066227.001]
  • [Cites] Int J Clin Oncol. 2006 Oct;11(5):339-43 [17058130.001]
  • [Cites] Dis Colon Rectum. 2004 Sep;47(9):1442-7 [15486739.001]
  • [Cites] Ann Surg. 1988 Oct;208(4):391-400 [3178328.001]
  • [Cites] Dis Colon Rectum. 1995 Nov;38(11):1162-8 [7587758.001]
  • [Cites] Cancer. 1996 Nov 1;78(9):1871-80 [8909305.001]
  • [Cites] Br J Surg. 1997 Apr;84(4):586-7 [9112939.001]
  • [Cites] Urology. 1997 Jun;49(6):822-30 [9187685.001]
  • [Cites] Br J Surg. 1998 Aug;85(8):1162 [9718031.001]
  • (PMID = 18365285.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2373867
  •  go-up   go-down


97. Hines RB, Shanmugam C, Waterbor JW, McGwin G Jr, Funkhouser E, Coffey CS, Posey J, Manne U: Effect of comorbidity and body mass index on the survival of African-American and Caucasian patients with colon cancer. Cancer; 2009 Dec 15;115(24):5798-806
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of comorbidity and body mass index on the survival of African-American and Caucasian patients with colon cancer.
  • BACKGROUND: There is a survival disparity between African Americans and Caucasians who have colon cancer.
  • METHODS: Data from patients (n=496) who underwent surgery for a first primary colon cancer at the University of Alabama at Birmingham Hospital from 1981 to 2002 were analyzed.
  • The confounding influence of comorbidity and BMI for the increased risk of death associated with African-American race was evaluated, and effect modification by disease stage for the association of comorbidity and BMI with mortality also was assessed.
  • The effect of comorbidity was observed among those with early stage tumors, whereas the effect of BMI was confined to patients who had advanced tumors.
  • CONCLUSIONS: Although comorbidity and BMI had an impact on the survival of patients with colon cancer after surgery, these variables were not contributing factors to the decreased survival observed among African Americans.
  • [MeSH-major] Adenocarcinoma / ethnology. Adenocarcinoma / mortality. African Americans. Body Mass Index. Colonic Neoplasms / ethnology. Colonic Neoplasms / mortality. Comorbidity. European Continental Ancestry Group. Health Status Disparities

  • MedlinePlus Health Information. consumer health - African American Health.
  • MedlinePlus Health Information. consumer health - Health Disparities.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 American Cancer Society.
  • [Cites] Gut. 2002 Aug;51(2):147 [12117867.001]
  • [Cites] JAMA. 2004 May 26;291(20):2441-7 [15161894.001]
  • [Cites] CA Cancer J Clin. 2004 Mar-Apr;54(2):78-93 [15061598.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3099-103 [15284260.001]
  • [Cites] J Clin Epidemiol. 2003 Mar;56(3):221-9 [12725876.001]
  • [Cites] Eur J Cancer. 2000 Mar;36(4):453-71 [10717521.001]
  • [Cites] J Natl Cancer Inst. 1995 Nov 15;87(22):1686-93 [7473817.001]
  • [Cites] J Chronic Dis. 1970 Dec;23(7):455-68 [26309916.001]
  • [Cites] Am J Gastroenterol. 2004 Apr;99(4):668-75 [15089900.001]
  • [Cites] Obes Res. 1998 Sep;6 Suppl 2:51S-209S [9813653.001]
  • [Cites] BMC Cancer. 2007;7:193 [17939875.001]
  • [Cites] Am J Clin Nutr. 2007 Sep;86(3):556-65 [17823417.001]
  • [Cites] J Clin Oncol. 2006 May 10;24(14):2179-87 [16682737.001]
  • [Cites] J Clin Epidemiol. 1999 Feb;52(2):137-42 [10201654.001]
  • [Cites] World Health Organ Tech Rep Ser. 1995;854:1-452 [8594834.001]
  • [Cites] J Natl Cancer Inst. 2006 Nov 15;98(22):1647-54 [17105987.001]
  • [Cites] Med Clin North Am. 2005 Jul;89(4):771-93 [15925649.001]
  • [Cites] Cancer Biomark. 2007;3(6):301-13 [18048968.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1739-57 [10738234.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Am Geriatr Soc. 1991 Aug;39(8):778-84 [1906492.001]
  • [Cites] Cancer. 1998 Jun 15;82(12):2312-20 [9635522.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):544-60 [12557158.001]
  • [Cites] Oral Oncol. 2005 Apr;41(4):358-64 [15792607.001]
  • [Cites] Cancer. 2003 Aug 1;98(3):484-95 [12879464.001]
  • (PMID = 19937953.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U54 CA118623; United States / NCI NIH HHS / CA / U54 CA118948; United States / NCI NIH HHS / CA / 5-RF25-CA47888; United States / NCI NIH HHS / CA / R01 CA098932; United States / NCI NIH HHS / CA / R25 CA047888; United States / NCI NIH HHS / CA / R01-CA98932-01; United States / NCI NIH HHS / CA / U54-CA118948; United States / NCI NIH HHS / CA / R01 CA098932-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS140672; NLM/ PMC2795032
  •  go-up   go-down


98. Hotokezaka M, Jimi S, Hidaka H, Ikeda T, Uchiyama S, Nakashima S, Tsuchiya K, Chijiiwa K: Factors influencing outcome after surgery for stage IV colorectal cancer. Surg Today; 2008;38(9):784-9
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors influencing outcome after surgery for stage IV colorectal cancer.
  • PURPOSE: According to the classification system of the Japanese Society for Cancer of the Colon and Rectum, Stage IV colorectal cancer is characterized by distant metastasis, which is defined by four factors: liver metastasis (H factor), metastasis to organs other than the liver (M factor), peritoneal dissemination (P factor), and distant lymph node metastasis (N factor).
  • We conducted this study to investigate the postsurgical prognosis of patients with Stage IV colorectal cancer (CRC), in reference to each of these four factors.
  • METHODS: We analyzed the medical records of 73 patients who underwent surgery for Stage IV CRC at our hospital between 1991 and 2001.
  • RESULTS: Univariate analysis revealed that P0 or P1 CRC (P < 0.001), absence of the M factor (P = 0.024), well or moderately differentiated adenocarcinoma (P < 0.001), resection of the primary tumor (P < 0.001), and curability B surgery (P < 0.0001) were associated with a better prognosis than other types of Stage IV CRC.
  • CONCLUSION: Surgery with curative intent should be considered for patients with Stage IV CRC defined by the P1 factor or H factor.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Colorectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18751942.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


99. Scheiden R, Pescatore P, Wagener Y, Kieffer N, Capesius C: Colon cancer in Luxembourg: a national population-based data report, 1988-1998. BMC Cancer; 2005;5:52

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colon cancer in Luxembourg: a national population-based data report, 1988-1998.
  • BACKGROUND: Over the last two decades time trends in incidence rates of colorectal cancer, changes in the proportions of stage at diagnosis and changes in the anatomic sub-site distribution of colon cancers have been reported in some European countries.
  • In order to determine a strategy for early detection of colon cancer in the Grand-Duchy of Luxembourg, all consecutive colon adenocarcinomas diagnosed during the period 1988-1998 at a nation-wide level were reviewed.
  • METHODS: The population-based data of the national Morphologic Tumour Registry report all new high-grade adenomas (i.e. high-grade intraepithelial adenomatous neoplasias) and all consecutive new invasive adenocarcinomas of the colon diagnosed in the central department of pathology.
  • Attention has been focused on variations in incidence, stage, anatomical site distribution and survival rates.
  • RESULTS: Over the study period, 254 new colonic high-grade adenomas and 1379 new invasive adenocarcinomas were found; the crude incidence rates of colon adenocarcinomas grew steadily by 30%.
  • Comparing the two 5-year periods 1988-1992 and 1994-1998, the crude incidence rates of high-grade adenomas (stage 0) rose by 190%, that of stage I cases by 14.3%, stage II cases 12.9% and stage III cases 38.5%, whereas the crude incidence rates of stage IV cases decreased by 11.8%.
  • The high-grade adenoma/adenocarcinoma ratio increased.
  • The overall observed 5-year survival rate (stage I-IV) was 51 +/- 3% (95% confidence interval).
  • CONCLUSION: The increasing incidence rates of colon adenocarcinomas, the persistence of advanced tumour stages (stage III), the mortality rates which remain stable, and the changing trends in the age- and sub-site distribution underline the need for preventive measures at the age of 50 in asymptomatic patients to reduce mortality from colo(rectal) cancer.
  • [MeSH-major] Adenocarcinoma / epidemiology. Colonic Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Med. 2001 Dec 1;111(8):593-601 [11755501.001]
  • [Cites] Cancer. 2001 Nov 15;92(10):2547-54 [11745188.001]
  • [Cites] Oncologist. 2002;7(3):200-4 [12065791.001]
  • [Cites] Gut. 2002 Jul;51(1):60-4 [12077093.001]
  • [Cites] Int J Cancer. 2002 Oct 10;101(5):403-8 [12216066.001]
  • [Cites] Dis Colon Rectum. 2002 Sep;45(9):1249-54 [12352244.001]
  • [Cites] Am Surg. 2002 Oct;68(10):871-6 [12412713.001]
  • [Cites] Eur J Cancer Prev. 2002 Dec;11(6):529-34 [12457104.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):544-60 [12557158.001]
  • [Cites] Jpn J Clin Oncol. 2003 Jan;33(1):38-43 [12604723.001]
  • [Cites] Scand J Surg. 2003;92(1):5-9 [12705545.001]
  • [Cites] An Sist Sanit Navar. 2003 Jan-Apr;26(1):79-97 [12759713.001]
  • [Cites] N Z Med J. 2003 May 16;116(1174):U437 [12766783.001]
  • [Cites] Surg Endosc. 2003 Jun;17(6):886-90 [12658426.001]
  • [Cites] Dis Colon Rectum. 2003 Oct;46(10 Suppl):S32-43 [14530656.001]
  • [Cites] Am Surg. 2003 Oct;69(10):866-72 [14570365.001]
  • [Cites] Dig Dis. 2003;21(4):315-9 [14752221.001]
  • [Cites] W V Med J. 2003 Sep-Oct;99(5):182-6 [14959509.001]
  • [Cites] Int J Cancer. 2004 May 1;109(5):777-81 [14999789.001]
  • [Cites] Am Surg. 2004 Mar;70(3):259-64 [15055851.001]
  • [Cites] BMC Cancer. 2003 Oct 21;3:27 [14567762.001]
  • [Cites] IARC Sci Publ. 1992;(120):178-861 [1284601.001]
  • [Cites] Semin Surg Oncol. 1994 Jan-Feb;10(1):12-20 [8115781.001]
  • [Cites] N Engl J Med. 2002 Jun 6;346(23):1781-5 [12050337.001]
  • (PMID = 15913456.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1173094
  •  go-up   go-down


100. Chin CC, Yeh CY, Tang R, Changchien CR, Huang WS, Wang JY: The oncologic benefit of high ligation of the inferior mesenteric artery in the surgical treatment of rectal or sigmoid colon cancer. Int J Colorectal Dis; 2008 Aug;23(8):783-8
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The oncologic benefit of high ligation of the inferior mesenteric artery in the surgical treatment of rectal or sigmoid colon cancer.
  • PURPOSE: It remains controversial as to whether high ligation of the inferior mesenteric artery (IMA) should be performed during surgical treatment for sigmoid colon or rectal cancer.
  • MATERIALS AND METHODS: From January 1995 to July 2001, a total of 1,389 patients underwent high ligation of the IMA; 387 patients featured non-disseminated sigmoid colon cancer and 1,002 patients had rectal cancer.
  • The beneficial rate of high ligation of the IMA for non-disseminated sigmoid colon cancer and rectal cancer was 0.8%, for non-disseminated sigmoid colon cancer 1.8%, and for non-disseminated rectal cancer, the rate was only 0.4%.
  • The rates of IMA metastasis in patients with T stage tumors were 0% (pT1), 1.0% (pT2), 2.6% (pT3), and 4.3% (pT4).
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Humans. Ligation / methods. Male. Middle Aged. Neoplasm Recurrence, Local. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18438677.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down






Advertisement